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Abstract
Integrins are heterodimeric cell surface receptors ensuring the mechanical connection between
cells and the extracellular matrix. In addition to the anchorage of cells to the extracellular
matrix, these receptors have critical functions in intracellular signaling, but are also taking
center stage in many physiological and pathological conditions. In this review we provide some
historical, structural and physiological notes, so that the diverse functions of these receptors can
be appreciated and put into the context of the emerging field of mechanobiology. We propose
that the exciting journey of the exploration of these receptors will continue for at least another
new generation of researchers.
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Chapter 1: Introduction and some historical notes
It is always difficult to trace back the origin of an idea, a particular historic event or the role of
its founders, that initiated a new way of thinking in a particular field of science. In the case of
the cell-matrix adhesion receptors of the integrin family, we could highlight the work of
Abercrombie and co-workers as well as Curtis, who explored the mechanisms allowing cells to
adhere to and crawl on petri dishes, recognizing the cytoskeleton and substrate anchoring
adhesion sites visible in the electron microscope or by interference reflection contrast (1, 2, 96).
Cell adhesion was also a subject interesting researchers in the field of tumor biology, as a central
feature of cancer cells is their ability to grow on soft agar, indicating that these cells no longer
require adhesion to their tissue environment and have lost the regulatory influence of the
healthy microenvironment of the tissue (273). At about that time, Richard Hynes incubated
normal adhering hamster fibroblasts or their hamster sarcoma virus-transformed derivatives
with an extracellular iodination solution. When analyzing the iodinated proteins by SDS-
PAGE, he identified an abundant 250 kDa protein present on normal, but not on transformed
cells (202). This large, external, and transformation-sensitive (LETS) glycoprotein was
simultaneously found and characterized in many different laboratories and given names such
as cold-insoluble globulin, cell surface protein, fibroblast surface antigen and eventually named
fibronectin (296, 375, 474). Since fibronectin showed an intriguing overlap with intracellular
stress fibers (204), the existence of a transmembrane link was postulated. Only a few years later
it became clear that fibronectin was a major extracellular binding partner for fibroblasts and
that the critical binding element in fibronectin was a short peptide Arg-Gly-Asp (RGD) (7,
334). The respective surface receptors recognizing this motif in fibronectin as well as in
vitronectin were identified by Pytela and Ruoslahti (349, 350). In an alternative approach, the
same fibronectin-binding surface receptors were also identified based on monoclonal antibodies
that prevented cell binding to fibronectin, such as JG22, CSAT and GP135 (8, 97, 158). Shortly
afterwards the integrin field enjoyed its first expansion phase, where all the different integrin
receptors and the majority of their ligands were described and named, either according to
biochemical or ligand-affinity data as in the case of fibronectin (a5b1) (349) and vitronectin
(avb3) receptors (350), or by researchers working in the field of immunology according to
antibody reactivity as for VLA1 to 6. Especially the latter field helped to develop the concepts
of integrin-dependent adhesion during platelet activation or cytokine-mediated adhesion of
leukocytes to the endothelium via (a4b1/VCAM-1) (110, 426) and LFA1 (aLb2)/ICAM-1
binding (117, 383, 406). Importantly, these integrin-dependent adhesion processes were not
constitutive, but could be triggered by cytokine stimulation and even b1-integrin-directed
adhesion-stimulating antibodies, proposing that the affinity of these cell surface receptors was
specifically regulated (22). The analysis of integrin receptors and their ligand specificity on the
vascular endothelium (85) eventually led to the idea, that the inhibition of integrin-dependent
adhesions in sprouting endothelial cells could inhibit the angiogenic switch and prevent tumors
from growing in the tissue (59, 138, 209), taking the research on integrin receptors to almost
all domains of biomedical research.
One of us was actually in the lucky position to assist this process, as his colleagues were actively
identifying, purifying and characterizing different members of the integrin family in the labs of
Jürgen Engel, Mats Paulsson and Ruth and Matthias Chiquet (193, 298, 423). It was clearly the
golden age, or alternative the “Sturm und Drang” period, of the integrin and extracellular matrix
research, in which most of the integrin-receptor concepts were created. In this phase also the
majority of the integrin knockout models were established in the labs of Richard Hynes,
Reinhard Fässler, Dean Sheppard and many others (111, 132, 198, 396), leading to the
quintessential integrin review published in 2002 by Richard Hynes (203).
About this time, first attempts were made to understand the structure-function relationship of
integrin receptors. First, the I-domain insert of the α-subdomain of the lymphocyte integrins
(aM) was crystallized in two different conformations, providing a strong argument for the
association of integrin ligand binding with conformational changes in the receptor (245). While
the I-domain of the a-subunit exhibited a single metal-ion-dependent ligand binding site, the
revelation of the structure of the entire extracellular domain of the avb3 integrin receptor,
identifying three differently complexed metal ions coordinating the RGD-peptide to the central
Mg2+ ion, determined a breakthrough in understanding how integrin-ligand-binding was
coupled to conformational changes of the integrin receptors (471, 472). The structural
differences between the headpiece of the lymphocyte integrin aM and the integrin avb3
expressed in fibroblasts and endothelial cells allowed first considerations about the connection
of integrin structure to physiological function (see Chapter 2).
It took a few additional years to understand the flexible elements of the integrins and the
allosteric conditions under which the receptor was extending into a conformation that was
compatible with ligand binding (470). Importantly the crystallographic studies with the aIIbb3
integrin ectodomain were backed up by electron microscopy analysis of individual integrin
heterodimers changing their conformation in the presence of Mn2+ ions and RGD peptides,
confirming the allosteric nature of the integrin receptor (125). With the analysis of other integrin
receptors, however, the debate continues about how conformational flexibility of the integrin
receptor and allosteric influence of intracellular adapters and extracellular ligands shape the
function of the different integrin receptors (289, 484) (see Chapter 2).
This second phase of in-depth analysis of the integrin structure/function relation was greatly
advanced by the discovery of the green fluorescent protein (GFP). The fusion of GFP to
cytoskeleton proteins or integrins allowed to localize these receptors in living cells, to study
their dynamic association in the plasma membrane and their cycling through the membrane
systems of the cell. In migrating cells, a different behavior of b3-GFP-integrin clusters located
at the front and at the rear of cells was apparent (35). Furthermore, the differences in the integrin
cluster behavior between immobile, but transient clusters in the cell front, and inward sliding
integrin clusters at the cell rear correlated with the dynamic exchange measured by fluorescence
recovery after photobleaching (FRAP) between these different integrin-dependent adhesions.
Interestingly, the dynamics of the integrin exchange depended on the regulation of the actin
cytoskeleton, providing at the same time a structural and dynamic vision of the integrin
receptors and their association with the actin cytoskeleton and integrin adaptor proteins such as
talin and vinculin (35, 90).
However, as we are learning more and more about the different integrin receptors, their
functions as well as mechanical and signaling capacities, we have entered a third and still
ongoing phase of research on the integrin receptor family. This third phase involves attempts
to integrate the notion of mechanosignaling with the mechanical aspects of cell linkage to the
extracellular matrix. Tensional forces created between the extracellular matrix and the
cytoskeleton induce changes in the extracellular visco-elastic scaffold, the integrin receptors as
well as their adapter proteins, linking intracellular signaling to conformational changes in
multidomain proteins (205, 450). In turn, such conformational changes can affect enzymatic
reactions and lead to activation of kinases such as focal adhesion kinase (FAK) and src family
kinases as well as different types of phosphatases. Thus, the large number of integrin-associated
proteins, defined as the adhesome (63, 239, 387, 492), as well as their differential interaction
with the plasma membrane is forming a puzzle consisting of 200 to 1000 different pieces, of
which we have only limited structural and biochemical information. Under tensional stress
many of these adhesome proteins will undergo conformational changes, further increasing the
complexity of the adhesion site. It remains a challenging task to identify the molecular
machinery, that has constantly evolved since the moment cells started to actively explore their
environment and to form multicellular organism relying on extracellular scaffolds.
Chapter 2: Structure and allosteric control of the integrin receptor
Overall integrin structure
As mentioned above, some integrins like aIIbb3, aVb3, and the integrins involved in
immunological functions containing the b2 subunit have been studied in more detail than other
members of the family, and many concepts in the field are based on these integrins. We
therefore want to give a general overview about the structural organization of integrins before
a more detailed discussion about structure and integrin activation based on aIIbb3 and aVb3
integrins. Finally, we extend the discussion to other integrins and the differences in their
organization before presenting potential consequences of integrin structure for their
physiological function (Chapter 3).
Ultimately, the understanding of the physiological roles of integrins requires to comprehend
the link of structural organization to adhesive function. Especially crystallography, electron
microscopy (EM), and conformation-specific antibodies have been pivotal to reveal different
conformations of integrins and the structural organization of the a- and b-subunits (Figure 1).
Both subunits are tightly bound to each other by interactions between the a-propeller and the
b-I-like domain in the extracellular “head” regions of both subunits. This association occurs in
the endoplasmic reticulum, and single chain integrins do not reach the cell surface (250).
Probably the most drastic structural difference between integrins is the presence or absence of
the ligand-binding a-I domain, inserted in the top part of the a-subunit (9 integrins have, 15 do
not have an a-I domain; see Figure 1). The a-I and b-I-like domains are structurally related to
the Von Willebrand factor A-domain, exhibiting both a metal ion-dependent adhesion site
(463). Although showing a similar fold, the b-I-like domain in the b-subunit of integrins
possesses some unique structural characteristics (see below). Integrins with an a-I domain
belong to the classes of collagen-binding integrins and leukocyte specific integrins (Figure 1)
and are found only in vertebrates. Functionally, the most obvious difference between integrins
with and without a-I domains is the mode of ligand binding. Integrins without a-I domains
bind ligands in a binding pocket formed by the a-propeller in the a-subunit headpiece and the
MIDAS ion in the center of the b-I-like domain of the b-subunit (Figure 2, 3). In contrast,
integrins with an a-I domain recognize ligands only with their a-I domain, which is however
structurally coupled to a b-I-like domain-binding  “IEGT” peptide motif, serving as an internal
integrin ligand (Figure 3D). Further analysis showed that the spatial arrangement of ligand-
integrin interactions is diverse even within the respective groups of integrins with or without
a-I domains (Figure 3).
Given the frequency of the RGD sequence in many extracellular matrix proteins, the group of
RGD-binding integrins is considered to recognize many different ligands. Because of the
importance of the RGD sequence motif, one might neglect the relevance of the structural
organization around the RGD peptide and the respective specificity of the ligand binding event.
While present in an exposed loop in fibronectin, the RGD-peptide is flanked by a helical motif
in the latent TGF-b binding protein, which leads to the specificity in binding to avb6 and avb8
(113, 321, 484). In addition, the initial characterization of integrin-ligand binding specificity
proposed the selective recruitment of the RGD ligands vitronectin and fibronectin to avb3 and
a5b1 respectively (349, 350). More recently, we have revisited ligand specificity by creating
binary choice substrates, that allow cells to simultaneously use their different integrin
populations on the most relevant ECM ligand (335). In fact, when cells were given the choice
between different substrates, the selection of the appropriate ligand was surprisingly specific,
suggesting that cells prefer to adhere on the most fitting adhesive surface in respect to ligand
density and stiffness. However, cells were also able to adhere to less-preferred ligands,
indicating that flexibility in ligand recognition might explain seemingly promiscuous integrin-
ligand binding. New techniques, e.g. single cell force measurements (233) and super-resolution
light microscopy (292) can detect differential ligand interaction in living cells (373), and will
certainly facilitate the reassessment of integrin-ligand interactions, their dynamic regulation,
and their in vivo behavior.
The ligand-recognizing headpieces of both a- and b-subunits are sitting on top of “leg”
domains (Figure 2), followed by transmembrane regions and, with the exception of b4 integrin,
comparably short cytoplasmic tails. While the extracellular headpiece binds ligands, the
cytoplasmic tails interacts with intracellular adapters. Especially the cytoplasmic tails of
b-subunits have been analyzed in detail and are attributed to important functions in regulating
integrin activity (see below) and actin linkage (Chapter 4). Functions and binding partners of
the cytoplasmic tails of a-subunits are less studied and have been associated with integrin
inactivation rather than activation and signaling (see Chapter 4 and (54, 344, 359)).
aIIbb3 and aVb3 integrin activation
Integrin activation (in terms of gaining the ability to bind ligands) is coupled to extensive
structural changes in both subunits. Currently, the prevailing model for aIIbb3 and aVb3
integrin activation assumes a tight coupling of integrin-ligand binding with a structural change
from a bent-closed to an extended-closed integrin conformation (‘switchblade model’; similar
to the opening of a Swiss army knife), and a further opening of the head piece to an extended-
open conformation (Figure 3E). All three conformations are present in the membrane in a
dynamically regulated equilibrium that involves intracellular adapters, as well as extracellular
ligands. Ligand binding affinity increases with integrin extension and head-piece opening.
However, also the bent conformation is able to bind RGD ligands (472). Nevertheless, the
structural rearrangement during integrin extension and subsequent head-piece opening is
accompanied by several local changes in the headpiece of the b-subunit induced by the carboxyl
binding of the Asp-side chain of the RGD-motif to the central MIDAS Mg2+ ion (Figure 3A,B):
(i) the ADMIDAS site moves towards the Asp-bound Mg2+ ion, (ii) the a1-helix in the b-I-like
domain straightens, (iii) the a7-helix makes a piston-like movement towards the hybrid domain,
(iv) which swings out, thereby increasing the angle to the b-I-like domain and completing the
headpiece opening (Figure 3). It seems that these discrete structural events cannot be uncoupled
during the process of headpiece opening; straightening the a1-helix by mutations leads to
increased overall integrin activation (495), as does constitutive hybrid domain swing-out by
introducing a glycosylation site that provokes opening of the angle between the b-I-like and
hybrid domain by steric interference (Figure 3A) (272). The structural integrin activation
process starts with a bent state and proceeds to the extended-closed and finally to the extended-
open state (347, 427, 500). In contrast to such a strict three-step process, Zhu and colleagues
showed that headpiece opening of aIIbb3 integrin is a continuous process, in which they
defined eight different steps (501). They also estimated the integrin headpiece affinity for an
RGD peptide in the open state to be more than 200-fold higher than in the closed conformation
and thus considered the extended-open conformation to be the active, ligand-binding state.
Moreover, recent electron microscopy data of different b1-integrin containing integrins,
proposes that the bent-closed conformation is not typical for these integrins, but regulated
essentially at the level of the integrin head-piece opening (289, 417). In addition, recent data
from our group indicates at least for aVb3 integrin, that the correlation between conformation
and ligand binding is more complex: aVb3 integrin locked in the extended-closed state was
able to bind vitronectin, but not fibronectin. Only the extended-open state of aVb3 integrin was
able to bind fibronectin, a behavior that required tensional forces acting on the integrin receptor
(31). Thus, structure-function relationships differ among ligands binding the same integrin,
suggesting that the extended-closed conformation might be more than just a ‘not yet activated’
integrin. A similar situation was demonstrated for α4b7 integrin, where two cytokines (CCL25
and CXCL10) cause different integrin conformations, binding either to MAdCAM or VCAM
(452). A explanation how the same integrin can select between different ligands was offered by
Cormier and colleagues (92). They argued that besides αVb3 integrin affinity for RGD, the
accessibility of the ligand to the integrin binding pocket might be a regulating factor. Figure 3
highlights some of the headpiece features influencing integrin ligand binding selectivity,
carrying the analysis also to laminin-binding integrins and how ligand accessibility and binding
can be enhanced by the integrin headpiece movement.  More detailed research will be required
to challenge the notion of RGD ligand promiscuity and to show how switching between
selective and promiscuous ligand binding can be of physiological relevance in vivo.
Given the extensive literature about mechanosensing and mechanotransduction by integrin
mediated adhesions, it is almost surprising that the experimental data about the influence of
mechanical forces on the integrin structure is rather limited. Based on molecular dynamics
simulations of aIIbb3 (500) and aVb3 integrin (347) it was hypothesized that mechanical load
on the b3-subunit facilitates the headpiece opening of the integrin by increasing the hybrid
domain swing-out. Therefore, one might argue that mechanical forces activate integrins, an
exciting concept contributing to the emerging field of mechanobiology. So far, this idea is
supported by experimental data for aLb2 integrin (LFA1) (292, 313) and aVb3 integrin (31,
83, 146). In line with this, b-integrin subunits are especially well suited to bear mechanical load
due to a reinforcement with two polypeptide chains (between the b-I-like and hybrid domain)
or a disulfide bridge in addition to a polypeptide chain between their domains (113). Domain-
connections in the a-subunit miss these additional reinforcements, and the a integrin subunit
may therefore unfold more easily under mechanical load.
Similarities and differences between integrins
Many cell culture studies compare aVb3 integrin and α5b1 integrin (34, 69, 98, 369, 388). Both
belong to the group of RGD integrins, bind fibronectin and are expressed in both fibroblasts
and endothelial cells. Accordingly, the overall structural organization is very similar.
Nevertheless, there are important structural and functional differences between aVb3 integrin
and α5b1 integrin. In a recent study, Takagi and coworkers detected aVb3 integrin to be present
in the bent, extended-closed, and extended-open conformation in the absence of ligands or
stabilizing antibodies (289). However, under identical conditions the authors failed to detect an
extended-open conformation for α5b1 integrin. In contrast, the group of Timothy Springer
detected all three conformations for α5b1 integrins by complexing them with conformation-
specific antibodies (417). This approach also allowed them to measure affinities of specific
conformations for RGD and fibronectin fragments (257). Interestingly, they detected a 4,000-
to 6,000-fold increase in affinity of the extended-open compared to the extended-closed
conformation for cyclic RGD (cRGD) and fibronectin fragments. This is in clear contrast to
αIIbb3 integrin, for which an only 200-fold increase was reported (501). This difference in
affinity increase during headpiece opening could imply α5b1 integrin to be ‘locked’ to its ligand
when reaching the extended-open conformation. Such a strong binding to fibronectin could
have evolved to support the mechanical stretching of the ligand during fibronectin
fibrillogenesis (390), which is likely to be a non-linear and visco-elastic process, in which a
rapid loss of tensional load in fibronectin fibrils should not result in the immediate dissociation
from the integrin receptor. On the other hand, the evolution of a synergy site in fibronectin,
specifically enhancing the on-rate for α5b1 integrin binding, may help to diversify the specific
features of certain integrin/ligand pairs (302). At the same time, a strong binding with a low
off-rate might also set the need for precise regulation of the activity of b1 integrins by inhibitors
(54) or by posttranslational modifications like phosphorylation, glycosylation, or acetylation.
This example emphasizes the connection of structural differences and specific physiological
tasks of a5b1 integrin in fibronectin fibrillogenesis. At the same time, it highlights the
difficulties of generalizing concepts from well-studied integrins to the entire family of integrin
receptors.
As mentioned above, collagen-binding integrins and leukocyte specific integrins differ from all
other integrins by the presence of an αI domain in the α-subunit. Importantly, only this αI
domain binds the respective ligand, in contrast to a combined ligand binding by both subunits
in integrins without αI domain. This might explain why RGD-binding integrins, lacking an αI
domain, evolved a bigger variety of α- and b-subunit pairings (Figure 1). Interestingly, the
initial binding pocket formed by the propeller domain in the α-subunit and the b-I-like domain
in the b-subunit is still present in αI domain integrins. However, it is used by the αI domain as
an intramolecular ‘pseudo-ligand’ for recognition of the IEGT-peptide motif (Figure 3D).
Additionally, αI domains have no ADMIDAS site, and their αI helix is always straightened
during activation. Thus, ADMIDAS movement towards the ligand and α1-helix straightening
during integrin activation might be used to fine-tune the affinity of the MIDAS site in b-I-like
domains (495, 501). Therefore, Zhang and colleagues (495) argued that αI-domain integrins,
missing this fine-tuning, might be better suited for fast on/off switching than integrins without
αI domain.
Another surprising mechanobiological feature of integrins are catch bonds between ligands and
integrins, meaning that the lifetime of a bond increases when force is applied (82). As
summarized by Cheng Zhu and colleagues (82), catch bonds are now described for α5b1 –
fibronectin, αVb3 – fibronectin, αLb2 – ICAM-1, α4b1 – VCAM-1, and αMb2 – ICAM-1. As
these authors point out, it is more appropriate to describe these bonds as catch-slip bonds, since
the bond will change from a catch bond to a slip bond when the force on the bond exceeds a
certain level. Catch bonds might have evolved to stabilize cell-ECM anchorage by allowing
integrin-ligand bonds to persist under mechanical load, especially when the other bonds in their
surrounding break by mechanical stress. Interestingly, catch bonds are documented also for
other receptor-ligand pairs than integrins (Notch-Jagged1, VWF-GPIbα, TCR-pMHC as
described by Cheng Zhu and colleagues (82); E-Cadherins (356), P-Selectin-PSGL-1 (281)), as
well as intracellular force-bearing connections like vinculin and actin (197). Potentially, catch
bonds will emerge as the rule and not the exception whenever mechanical forces are involved
in receptor ligand interactions. Still, the structural implementation of this feature within the
integrin headpiece requires yet to be shown. The increasing unmasking of the positive charge
of the metal ion at the MIDAS position and the consequentially tighter binding of the negatively
charged Asp in the RGD peptide during integrin activation are, however, a plausible mechanism
(458, 459) (Figure 2, 3). Catch bonds in aI domain integrins aLb2 and aMb2 have to include
the aI domain, but mechanisms in the b-I-like and hybrid domain could be analogous in
integrins without aI domain (82).
The in vivo importance of catch bonds might be best documented in the vasculature, where
selectin-based catch bonds regulate leukocyte rolling in presence of shear stress caused by the
blood stream (139). Additionally, recent examples of circulating tumor cells arresting in a b1-
dependent manner in the blood flow might indicate the relevance of catch bonds (281).
On a first glance, the structural understanding of integrins might appear quite detailed already.
However, as described here, not every integrin is studied to the same extent, and the
generalization of individual integrin qualities to other integrins might be misleading. While
structural features of integrins can be linked to physiological settings, it is also clear that we are
limited by techniques that allow us to test these hypotheses in vivo. Additionally, the examples
of mechanical integrin regulation suggest that the transfer of data from experiments in the
absence of force (in vitro studies, flow cytometry) to the in vivo setting is not always
straightforward. Having said this, we are nevertheless convinced that the detailed understanding
of even a few integrins will be useful as a framework to compare with other integrins, deducing
their function based on differences and similarities.
Chapter 3: The physiological role of integrin-dependent cell adhesion explained through
several examples
Integrin affinity modulation versus clustering in the plasma membrane (talin and kindlin)
When integrins recognize extracellular ligands and change from a low to a high affinity
conformation, either by an outside-in or inside-out triggered mechanisms, they also start to form
clusters in the membrane that are visible by light microscopy (35, 90, 336). Using super-
resolution light microscopy, the initial formation of nano-clusters of 50 to 100 ligand-bound
integrins can be detected (75), that will further assemble into larger integrin clusters to enable
cell adhesion. The mechanistic connection between conformational activation of b3-integrins
and integrin clustering is still not fully understood, but requires at least extracellular ligand-
binding, talin-head/integrin interaction and talin and kindlin binding to phosphoinositol lipids
in the plasma membrane (51, 90).
Although aIIbb3 and avb3-integrin activation and clustering are among the best studied
integrin processes, it is still not clear, why in resting platelets a2b1 integrin is in an apparently
extended, ligand binding-competent, but not fully activated state  (289, 312), while at the same
time aIIbb3 receptors are thought to be present in the platelet membrane in a bent-closed
conformation (485). Differences between b1 and b3-integrins in the transmembrane and
cytoplasmic a-domain association, also known as the inner membrane clasp (Figure 2), could
account for these different integrin resting states (271). Similarly, intracellular isoform-
selective integrin inhibitors could be responsible for maintaining distinct conformational pools
of cell surface integrins, e.g. keeping aIIbb3 in a bent-closed conformation and preventing it
from binding plasma fibrinogen, while presenting a2b1 in an extended conformation able to
bind to exposed collagen fibers at sites of vessel damage (441). Support for the model of
conformational activation of aIIbb3 integrin has come mainly from the discovery of a ligand-
mimetic IgM monoclonal antibody (PAC-1) binding aIIbb3 integrin on activated, but not
resting platelets (394). Interestingly PAC-1 exhibits an RGD-related KYD sequence in the H3
loop of the heavy chain, thought to be responsible for aIIbb3 binding. However, a report by
Tomiyama and coworkers described two different IgG antibodies with the same KYD sequence
that bound equally well to resting as well as activated platelets (439). Although this discrepancy
in aIIbb3 binding by IgG and IgM antibodies can be explained by a specific conformation of
the KYD-containing loop, probing aIIbb3 integrin binding with Fab fragments of the PAC-1
antibody did not allow to discriminate between integrins on resting or talin-head activated
platelets or CHO cells (62). Thus it appears possible that the large size of the PAC-1 IgM
prevents it from efficiently recognizing the bent-closed aIIbb3 integrin receptor. On the other
hand it is also likely that the enhanced cell surface binding of PAC-1, e.g. observed during talin-
head mediated aIIbb3 activation (425), is due to talin-mediated (90, 380) or kindlin-induced
integrin clustering (486). Such an increase in integrin clustering is particularly well detected
due to the polyvalency of the PAC-1 ligand (62), therefore proposing that physiological inside-
out activation of the b3-integrin receptor involves conformational changes of the integrin
ectodomain as well as adapter-induced clustering of the receptors in the plasma membrane (90,
380). Kindlin appears to contribute to integrin clustering rather than to activation, co-operating
with talin in this process (486).
The conformational activation of integrins has also been analyzed by a genetic screening
approach based on a monovalent integrin ligand binding to the Drosophila aPS2bPS integrin.
This study revealed mostly gain of function mutants in bPS, stressing the physiological
importance of keeping integrins in a low ligand-binding affinity state. On the other hand, the
mutation of the juxtamembrane CGFFNR sequence in aPS2 to CGFANA enhanced ligand
binding of the integrin, while the VGFFNR mutation led to a reduction of ligand binding (187,
220). Interestingly, the mutated cysteine residue is conserved in a3, a6, a8 and aE-integrins
(Figure 1) and known to be palmitoylated in a3 and a6-integrins (480),  proposing the existence
of still undiscovered mechanisms to control the integrin affinity state in general (such as
kindlin) or in integrin-specific situations, such as in aPS2.
The aIIbb3 receptor on platelets
One of the best studied integrin structure-function relationship concerns the aIIbb3 receptor
expressed on platelets. Blood is coagulating through activation of platelets, that are stimulated
by agonists such as ADP or thrombin, or by binding to injury-released, collagen-bound von
Willebrand factor, leading to a conformationally induced change in the affinity of aIIbb3
integrin (also known as  GPIIb/IIIa) for circulating fibrinogen in the plasma (470). Based on
this physiological example, the signal-mediated conformational change of aIIbb3 integrin and
the subsequent binding of extracellular fibrinogen allowed to establish the concepts of inside-
out and outside-in signaling. The activation of aIIbb3 integrin has to be strictly regulated to
avoid a fatal thrombosis, therefore it cannot be activated by the always-present ligand
fibrinogen. Instead, intracellular signals are required for aIIbb3 integrin activation, leading to
fibrinogen binding and formation of a blood clot (i.e. inside-out signaling). These activating
signals for aIIbb3 integrin, on the other hand, have to originate from the outside, where a signal
conveying the presence of a wound to the platelet triggers the intracellular cascade leading to
aIIbb3 integrin activation (i.e. outside-in signaling). Platelets express the collagen receptors
GPVI and a2b1 integrin, both potentially sensing wound-exposed collagen, but the precise
contribution of both receptors to aIIbb3 integrin activation appears controversial (279, 309).
Recent structural studies for b1 integrins in the presence and absence of ligands revealed
interesting differences to b3 integrins with consequences for the structure-function relationship
of both integrins. Takagi and coworkers found b1 integrins in the absence of ligands to be
mostly present in the extended-closed conformation, irrespective of the ion conditions (289).
The same study, but also work by the group of Timothy Springer (417), detected extended-open
conformation for b1 integrins in the presence of ligands (or stabilizing antibodies). On the other
side, b3 integrins conformations were strongly affected by ion conditions, revealing
conformations from bent, extended-closed to extended-open. Thus, b3 integrins might be more
susceptible to allosteric regulation by cytoplasmic adapters, while b1 integrins are mostly
regulated by the presence of ligands.
The inside-out activation of aIIbb3 integrin is still a matter of research, but essential features
include the activation of the Rap-1 GTPase, binding the talin rod-domain to release talin
autoinhibition and to induce a mechanical coupling between the actin cytoskeleton (talin rod
domain) and the integrin-cytoplasmic tail (talin head domain) (64, 230, 416, 454). Since the
talin-integrin connection provided an explanation of the aIIbb3 integrin activation mechanism,
critical roles for additional integrin activators were not considered at the time. However, it has
become clear, that the talin-head interaction with the cytoplasmic tail of the b3-integrin receptor
alone is not sufficient, and that the plasma membrane-associated adapter protein kindlin is at
least equally, if not even more important than talin to induce aIIbb3 integrin conformational
activation and fibrinogen binding, subsequently triggering platelet and cell spreading (295, 437)
(Figure 2, 3).
Several publications indicated Rap1-mediated activation of integrins to include the binding of
RIAM to talin, as demonstrated for aIIbb3 integrin (179). Recent publications analyzed this
process in more detail and found RIAM-mediated activation to be specific for b2 integrins,
whereas within the same leukocytes a4b1 integrin is activated in a RIAM-independent manner
(230, 414). Additionally, RIAM knockout mice showed no severe phenotype and unaltered
b1 and b3 integrin activation (230, 414). Thus, it appears that pathways upstream of talin (and
kindlin) are able to target and activate specific integrin subunits, enabling cells to react
differentially to separate outside-in signals. One of these pathways may involve a direct
activation of the talin-head domain by Rap1-binding, instead of an indirect, RIAM-dependent
mechanisms (58, 68, 502).
The role of integrins in extracellular matrix assembly: fibronectin
So far we have mainly considered the role of integrin receptors in a cell-autonomous way, as
integrins are critical for cell anchorage to the extracellular matrix, providing signals for survival
and proliferation. However, integrin receptors are also used by cells to organize or remodel the
extracellular matrix. For example, cultured fibroblasts synthesize extracellular matrix proteins
such as fibronectin, which they incorporate into an extracellular scaffold that allows their
adhesion and generates survival signaling. In the well-studied case of fibroblasts cultured on
fibronectin, the avb3 integrin receptor assures the binding of the cell periphery to the culture
substrate, while a5b1 is “spinning” or “weaving” a fibronectin network around the center of
the spread cells by forming fibrillar adhesions (324). In a preformed 3D fiber network the
classical distinction between focal and fibrillar adhesion is no longer maintained (95, 473). As
mentioned in Chapter 1, transformed fibroblasts loose the capacity to synthesize fibronectin
fibrils. In cancer tissues cancer-associated fibroblasts partially compensate this by excessive
deposition of extracellular matrix in the tumor stroma (CAFs) (126, 316). Interestingly, the
enhanced deposition of extracellular matrix by CAFs should be taken into consideration during
the treatment of tumor patients, as the enhanced stiffness of the tumor stroma induces survival
signaling in B-RAF inhibitor-treated melanoma cells (191). The mechanisms responsible for
fibronectin fibril synthesis are still incompletely understood, but involve the cytoplasmic
integrin adapter protein tensin1 (324). Interestingly tensin1 function is targeted also by
intracellular metabolic pathways, linking integrin-dependent fibronectin assembly to the level
of glucose in the tissue and in general to the metabolic state of a cell in a tissue (157, 288).
Moreover, the tracking of fluorescent b1-integrin in astrocytes has allowed to connect the
assembly of fibronectin fibers in fibrillar adhesions to the simultaneous association of GFP-
labeled VEGF with such newly synthesized fibronectin fibers (119). These results do not only
provide a unique insight into the process of integrin-dependent fibronectin assembly, but also
highlight the fact that the extracellular matrix is providing a delicately tensioned scaffold,
binding and storing growth factors and releasing this pool of signaling molecules in the case of
tissue injury or pathological signaling in the case of fibrosis (see Chapter 9). Rather recently, it
became evident that not only tensins, but also proteins from the kank family are relevant in
fibrillogenesis (420). Kank2 reduces the affinity of the talin rod for actin, thereby weakening
the mechanical load on the ECM-integrin-actin axis. This process acts in parallel to the
maturation of focal adhesions to fibrillar adhesions and their translocation to the cell center. It
might be counterintuitive that mechanical alignment of fibronectin fibers is mediated by
fibrillar adhesions under low mechanical load. Interestingly, detailed studies with atomic force
microscopy revealed that the initial reorganization of fibronectin fibers already occurs in the
cell periphery, where integrins are under higher mechanical load (174). Thus, we envision a
model of initial fibronectin stretching in the cell periphery, including higher forces on the
integrin-fibronectin link. After this opening of cryptic binding sites on fibronectin, and
potentially detachment from the substrate, small fibrils are aligned and organized to form bigger
fibrils. This translocation of detached fibrils might benefit from high-affinity binding even
under low force, which is achieved by a5b1, but not by aVb3 integrin (31, 388), while kank2
orchestrates the change in force level through the modulation of the talin-actin connection.
Interestingly, kank2 might also be important for the effect of microtubules and focal adhesion
stability (77). Kank binds simultaneously to the CLASP family of microtubules plus-end
binding proteins, the R7 subdomain of talin, as well as the membrane-bound liprin/LL5
scaffold, which functionally associates focal adhesions with the vesicular transport machinery
(53, 410).
The role of integrins in extracellular matrix assembly: laminin and collagen
Collagen and fibronectin are both major components of the ECM, responsible for the structural
organization and mechanical integrity of the ECM. Collagen type I is a prime example for
fibrillar collagens, in contrast to collagen type IV that forms networks in the basement
membrane. Four integrins,  a1b1, a2b1, a10b1, and a11b1 (all containing an a-I domain; see
Figure 1), are reported to bind collagens with certain preferences for either collagen I or
collagen IV (222). Both collagens also have different mechanisms leading to their structural
arrangement in the ECM. Collagen I is known to align with fibronectin and to gradually replace
it in the ECM during wound healing (287). Interestingly, collagen I preferentially binds to
relaxed fibronectin fibers (236). On the other hand, the same study (236) showed fibronectin
fibers to be under increased stress in the absence of collagen I, thereby emphasizing the
relevance of collagen for the mechanical state of ECM. A self-assembly of fibrillar collagen,
used for surface coatings in cell culture studies, seems to be much less relevant in vivo (215).
The experimental observation of the basement membrane organization and its main components
collagen IV, laminin, nidogen, and perlecan in epithelial cells is more complex. Collagen IV
was shown to be dispensable for the initial organization of the basement membrane in the
embryo (before E10 in mice), but to be essential in later developmental stages (341). Thus, like
fibrillar collagen, also collagen IV is highly important for the structural integrity of the ECM.
It is well accepted that in basement membranes a3b1, a6b1 and a6b4 integrins contribute to
adhesion of epithelial cells by recognizing the c-terminal globular domains of the laminin a-
subunit (see also Figure 3D) (483). In the absence of these integrins, the epithelia detach and
blisters form (111, 112). Defects in the deposition and organization of such basement
membranes have been rarely reported, but it has been recognized that laminin binding integrins
are palmitoylated in either their a3, a6 CGFFKR sequence or b4-juxtamembrane domains
(480). The absence of this reversible lipidation affects laminin-dependent adhesion and
association with the palmitoylated tetraspanins in the plasma membrane (39, 479).
Interestingly, the depletion of the tetraspanin CD151 causes kidney failure associated with
altered glomerular basement membranes (378). Moreover, in tissue culture a3b1-integrins
showed enhanced, focal adhesion-like clustering due to the absence of the tetraspanin CD151
(377), suggesting that membrane distribution and tetraspanin association of laminin-binding
integrins are not only regulating the adhesion to basement membranes, but also their assembly.
Non-classical integrin mediated adhesions
Integrin-mediated adhesions were often classified according to a maturation sequence starting
from nascent adhesions, leading over focal complexes and focal adhesions to fibrillar adhesions
(88, 151). However, it is also clear that not all integrin adhesions follow this scheme.
Podosomes and invadopodia (now summarized as invadosomes) were already described in the
1980s (reviewed in (195, 300)), and their structural organization differs drastically from
‘classical’ integrin adhesions. Invadosomes have a central actin core oriented perpendicular to
the substrate and surrounded by a belt of adhesome proteins like talin and vinculin. As the name
indicates, invadosomes are involved in ECM degradation, thereby supporting invasion of the
cell into the degraded, softened tissue. This is achieved by the delivery of matrix
metalloproteases (MMPs) to sites of invadosomes, where they are secreted and digest the ECM
(338). This process was shown to also occur at focal adhesions (410), but appears to be more
prominent at invadosomes. For more insights about integrin recycling and endo- and exocytosis
at sites of integrin adhesions we would like to refer to excellent reviews about this topic (142,
293, 328).
More recently, a new type of adhesions specific for αVb5 integrin emerged (270). During the
analysis of integrin adhesions throughout the cell cycle the authors detected an enrichment of
b5 integrin to specific adhesion structures during interphase. Interestingly, αVb5 integrin-
mediated adhesions in these cells recruited no classical adhesome proteins like talin1, kindlin2
or vinculin and were not coupled to actin filaments. Additionally, their shape differed from
classical adhesions; they formed a dense net of adhesive structures coined reticular adhesions.
The reticular adhesions recruited adapters of clathrin-mediated endocytosis, potentially
contributing to their ability to stay attached to the matrix during mitosis and to serve as a
‘adhesion memory’ during re-spreading after mitosis. Additional studies by other groups
confirmed this dependence of αVb5 integrin-mediated adhesions on adapters of clathrin-
mediated endocytosis, in contrast to classical adhesome proteins (38, 503). Interestingly, αVb5
integrin adhesions associated with clathrin adapters have a capacity for mechanosensing and
mediate cell adhesion even in the absence of the classical adhesion machinery. b5 integrin
knockout mice develop age-related retinal dysfunction due to the lack of b5 integrin-dependent
phagocytosis of photoreceptors by retinal pigment epithelial cells (304). The relation of this
finding to reticular adhesions in cell culture experiments remains to be shown in future
experiments.
Forces in tissues
The third phase of integrin research, reconciling known features of integrins with their ability
of mechanosensing and -transduction, is presumably just beginning. But can we expect that
these findings have a relevance in more physiological settings, compared to cells cultured on
glass and plastic coated surfaces? We believe that recent findings strongly suggest important
roles of mechanical parameters (e.g. tissue stiffness, ligand geometry, elasticity vs. visco-
elasticity) in developmental and pathological settings. As we discuss in Chapters 6 and 9,
integrin-mediated mechanotransduction follows a sigmoidal mechanoswitch triggered around
5 kPa substrate stiffness. It is striking that most healthy tissues have a stiffness below this point,
while fibrotic tissue is stiffer than 5 kPa (see Chapter 9). At the same time, stiffness gradients
observed during the development of Xenopus (438) and Drosophila (94) make clear that
developing organisms consist of regions with distinct mechanical properties. Richard Harland
and coauthors showed in elegant experiments that the positioning of feathers in developing
chicken skin is based on mechanical signals (401). Therefore, it will be not surprising when
more reports uncover the contribution of integrin mechanosensing and -transduction in
development and pathologies. On a more structural level, it is interesting to note that both talin
(265) and integrins (422) are aligned with the force vector of actomyosin forces. As mentioned
in Chapter 2, MD simulations suggest that forces parallel to the membrane (imitating retrograde
actin flow) support the extended-open conformation of αIIbb3 integrin, while the extended-
closed conformation is stabilized by forces perpendicular to the membrane (422, 500).
Additionally, work in Drosophila indicates that integrins and talins might experience unique
force vectors in different tissues (229). Combined with the findings that specific integrin
conformations bind ligands selectively (see above), differential force vectors in tissues might
be a mechanism to tune the physiological needs for integrin activation and signaling. This very
likely includes also mechanical regulation of integrin adapter conformations (208). However,
the testing of these hypotheses will require improved tools to measure forces and force vectors
in vivo. Several studies in Drosophila offered interesting insights into this question and might
indicate a renaissance for this model organism (166, 172, 229, 249, 431).
Chapter 4: Regulation of integrins by adapter proteins
Integrins recruit hundreds or even up to thousand different proteins, building the so-called
adhesome (63, 239, 387). However, a recent meta-analysis defined a consensus adhesome of
60 proteins (194), that the authors organized in four groups: 1) ILK – PINCH - kindlin, 2) FAK
- paxillin, 3) talin - vinculin and 4) α-actinin – zyxin – VASP. Most of these proteins have been
mapped into functional layers with super-resolution imaging (217). The importance of these
sets of proteins is reflected by their frequent discussion in reviews on integrin-mediated
adhesions (199, 207, 208, 364, 371, 419).
For this review, we wanted to focus on adapters that directly bind integrins. Therefore, we
curated a list of such direct integrin adapters (Table 1). Some of these proteins, like talin or
FAK, are well known in the integrin field, others are less well studied and their effect on
integrins might not be fully established yet. Additionally, the large diversity of the integrin
family as well as their extensive functional diversity suggests that integrins are regulated in a
cell- and integrin-type specific manner. For example, kindlin3 is only expressed in
hematopoietic cells (49) but kindlin1 and kindlin2 show unique interactions with integrins in
keratinocytes (36), indicating that they are not functionally redundant (371). Talin1 and talin2
are shown to influence mechanotransduction differently (26) and to possess altered affinity for
the β1- and β3-integrin subunits (15). They also differ in their expression within tissues, with
e.g. talin2 being the dominating form in striated muscle (392) and required for fibronectin
assembly (345). Nevertheless, the knockout of talin1 is embryonic lethal, while talin2 knockout
mice show a dystrophic phenotype (104). We assume that further detailed and isoform-specific
analysis will reveal more selective integrin-adapter interactions and their evolution for specific
physiological needs.
To support a conceptual understanding of integrins we want to introduce 5 functions that are
mediated by integrin adapters: (i) activation, (ii) inactivation, (iii) inhibition, (iv) signaling, and
(v) mechanosensing. We expect that less-studied adapters can be explained within the
framework of these functions. This classification also implies that adapters can have more than
one function.
Activation
Talin and kindlin activate integrins (= change the extracellular conformation)  and increase their
affinity for ligands in a process of inside-out activation involving interaction of these adapter
proteins with the b-integrin cytoplasmic tail. Both talin and kindlin are required for integrin
activation and clustering, but appear to differentially contribute to mechanosensing (talin) and
signaling (kindlin) (354, 437). An important part of integrin activation are the unclasping of the
a- and b-subunit at the level of the transmembrane and cytoplasmic tails as well as the physical
connection to the actin cytoskeleton. The a-integrin cytoplasmic tails vary in sequence and
length, but share a common GFFKR motif partially buried within the cell membrane interacting
with the transmembrane domain of the b-subunit (Figure 4 and 7). The cytoplasmic tails of
b-integrins contain two conserved PTB (phosphotyrosine-binding domain) binding sequences
(Figure 7): the membrane-proximal NPx(Y/F) and membrane-distal Nxx(Y/F) motifs. Talin
binds both the membrane-proximal helix and the b-integrin tail up to the first, membrane-
proximal NPx(Y/F) motif (16, 150, 457). Kindlin binds to the inter-NXXY-region and the
membrane-distal Nxx(Y/F) motif (253). Talin and kindlin can thus bind integrin simultaneously
(46). Furthermore, the binding of paxillin to kindlin has been found to promote integrin
activation (149), potentially further increasing the complexity of the integrin activating
intracellular adapter complex. As shown for some integrins, outside-in activation is triggered
by ligand binding, and therefore also ligands can be considered as integrin activators.
Additionally, mechanical load supports integrin activation (see Chapter 2) and could therefore
be considered as an activator. In this context, it is important to note that the F-actin linkage to
integrins is the mechanically weak point, where integrin clustering, recruitment of adapter
proteins (such as vinculin) and regulation of actin (de)polymerization are likely to be involved
(200, 327).
Inactivation
Integrin inactivators ensure the dynamic regulation of cell adhesion, e.g. by unbinding from
areas a cell wants to avoid, allowing migration away from this location. Phosphorylation by
kinases, most notably FAK and Src, increases the turnover of integrins and integrin-mediated
adhesions. Src serves as an integrator of several pathways, as it was shown that local ephrin/Eph
signaling influences integrin-mediated adhesions in its vicinity via a Src-FAK-paxillin cascade
(84). Additionally, endocytosis allows integrin detachment from the ECM and thereby
inactivates integrins: Dab2/clathrin-mediated endocytosis was shown to replace integrin
activators like talin and kindlin from b3 integrin and to mediate integrin endocytosis (488).
Interestingly, Dab2-mediated endocytosis was increased in the absence of mechanical load on
integrins, indicating that a lack of force can participate in integrin inactivation. Thus, there
might be different ways integrins can be inactivated, involving either an inside-out mechanisms,
e.g. proteolytic degradation of adapter proteins (386), or phosphorylation of integrins or
adapters (as review, see (148)). On the other hand, the proteolytic degradation of extracellular
matrix generates protein fragments with intact integrin binding functions. Such ECM
fragments, also termed matrikines, can bind to integrins in their soluble forms, maintaining the
extended-open conformations of integrins without mechanical linkage to the ECM. At this
point, it is not clear why such a tension-free state would enhance the exchange of talin with
other intracellular adapters, but it leads to the subsequent internalization of the complex, as
observed for fibronectin-bound receptors (76, 269).
As just mentioned, an interesting aspect of integrin activation vs. inactivation is the role of force
in these processes. Why are activators and inactivators needed, if increased mechanical load
activates integrins and decreased mechanical load inactivates them? First of all, it is important
to keep in mind that force needs a physical link to be transmitted: there is no relevant
mechanical force on integrins without talin-mediated actin linkage (354). Maybe even more
importantly, integrins are not purely mechanical anchors, but also measure tension, create and
integrate biochemical signals that in turn will change cell adhesion, motility and proliferation.
These different integrin functions should be reflected by different modes of integrin
(in)activation. At the same time, the crosstalk between different modes of integrin activation
would allow to integrate mechanical and biochemical signals at the level of cell adhesion.
Inhibition
Some integrins are found in the membrane in an inactive, bent conformation (see Chapter 2).
Additionally, the pool of inactive integrins can be stabilized or increased by integrin inhibitors
(summarized in (54)). ICAP, for example, binds to the tail of b1 integrin and prevents activation
(61), while filamin A is shown to inhibit integrin activation by establishing a ternary complex
with αIIb and β3 integrin subunits, preventing the separation of the integrin subunits (264) (see
Figure 3E).
Signaling and Mechanosensing
Finally, some adapters of integrins are involved in signaling or mechanosensing. Signaling
adapters include kinases like FAK, but also paxillin, that serves as a dynamic scaffold recruiting
different GEFs and GAPs, thereby regulating Rho-GTPases signaling and the organization of
the actin cytoskeleton (103). Mechanosensing adapters, on the other hand, include e.g. the Src-
substrate p130Cas, that is phosphorylated upon cell stretching (385). The ability of adapters to
sense and transduce mechanical signals is often coupled to force-mediated conformational
changes (208). Talin is an example, having several cryptic vinculin- and hidden actin-binding
sites that become accessible when the talin rod domain is put under tension (24, 353, 365). In
turn, the tension-exposed vinculin binding sites will enhance the physical anchorage of the talin
rod to the actin cytoskeleton via newly recruited vinculin. The examples of FAK and talin
illustrate that the same adapter can fulfill different tasks, according to the functional
classification presented here.
The slanted fence model of focal adhesions
What can we say about the spatial organization of integrin adapters within focal adhesions?
Super-resolution light microscopy has allowed the analysis of integrin-dependent adhesions in
great details. This strategy involves on the one hand the analysis and tracking of individual
integrin receptors in living cells, on the other the identification of the spatial organization of
key adhesion components (217, 373). In fact, tracking of individual b3 or b1 integrins in living
cells revealed the transient immobilization of these receptors within paxillin-positive focal
adhesions (373, 456). Moreover, cytoplasmic adapter proteins such as talin were directly
recruited from a cytoplasmic pool into focal adhesions, suggesting that the stabilization of the
talin/integrin interaction seen e.g. during talin-induced integrin clustering occurs inside the
adhesions themselves and not as a precursor outside of adhesions. The analysis of elongated
focal adhesions by interferometric photoactivated localization microscopy (iPALM) has
revealed specific membrane distances for different types of integrin adapter proteins. While the
paxillin/FAK/src module is located in a membrane-proximal “signaling layer”, the c-terminal
F-actin binding region of talin is located distant from the membrane within the F-actin and
vinculin cross-linking domain of focal adhesions. Moreover, the local tension induced on the
talin-rod domain is directly reflected by the orientation of the F-actin network forming the
backbone of adhesion (238). If these positional informations are integrated with the lateral F-
actin/myosin tension as well as the recent interactions of paxillin and DLC within the talin R8
bundle (491), one possible orientation is that of a slanted fence, similar to mobile fence systems
used in the alpine regions. These slanted fences are stabilized by slanted long poles,
representing the extended talin and F-actin fibers, and held in place by vertical poles, laterally
connecting the fence structure (see for example
https://de.wikipedia.org/wiki/Zaun#/media/File:Schrankzaun2.JPG).
For focal adhesions, we are proposing that the flexible regions in paxillin and FAK could serve
as dynamic connectors between the different layers of the focal adhesion, reacting to force
changes in the lateral as well as vertical axis of the tethered talin-rod domain (Figure 6). As for
the slanted fence, such a dense interaction in lateral and axial direction would increase the
stability of the system against perturbations from multiple directions.
Table 1 Integrin cytoplasmic adaptors and their known properties. The abbreviations of the detection methods are AC:
affinity chromatography, B: biosensor assay, EA: enzyme assay, ELISA: enzyme-linked immunosorbent assay, IP:
immunoprecipitation, ITC: isothermal titration calorimetry, NMR: nuclear magnetic resonance spectroscopy, PD: pulldown
assay, XRAY: X-ray crystallography, Y2H: yeast two-hybrid, O: other. The PDB code refers to the available structural
information in the Protein Data Bank (42). IBS1 and IBS2: integrin binding sites 1 and 2 in talin. The list is not exhaustive.
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Dab1 β1A, β3 membrane-distal NxxY PD (65) adaptorprotein
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Tensin-1 β1A, β3 β1A: KWDTGENPIYKSβ3: KWDTANNPLYKE B (284)
actin binding
Tensin-2 β3, β5,β7, β1A PD (65)
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Chapter 5. Proliferation and YAP/TAZ signaling
Proliferation
Integrins are usually considered to be cell-matrix receptors. This might be mistaken as a passive
“gluing” to a substrate, offering a mere structural link to the cytoskeleton. Telling the story of
the paxillin discovery, Christopher Turner described this as the “dogma of the time” for
integrin-mediated adhesions (103). Fittingly, integrins possess no kinase domain, potentially
enhancing this belief at the beginning of integrin adhesion research. Still today, integrins and
integrin-mediated adhesions are sometimes just regarded as a structural link to actin und
intermediate filaments. Nevertheless, there is no doubt about the signaling capacity of integrin-
containing adhesive structures. Already early on, integrin-mediated adhesions were shown to
have elevated levels of tyrosine phosphorylation in v-Src transformed cells (161). On the other
hand, endothelial (286) and epithelial cells (147) undergo apoptosis after detachment from the
ECM (i.e. anoikis). Both examples, anoikis and increased phosphorylation after v-Src mediated
immortalization, highlight the link of integrin signaling to proliferation. Anoikis is regulated by
a FAK-p53 signaling axis (259), while YAP/TAZ proteins regulate substrate stiffness-
dependent proliferation (see below). Especially the YAP/TAZ pathway has attracted a lot of
attention in the last years, as it forms a link between mechanical input and cell proliferation.
However, it is interesting to note that the MRTF/SRF signaling pathway acts in parallel to and
shares certain target genes with the YAP pathway (140). Additionally, the MRTF/SRF pathway
targets also genes independently of YAP, which mediate a phenotype often associated with
increased YAP/TAZ signaling (140, 188).
YAP/TAZ
As integrins are increasingly recognized as mechanosensors, we want to discuss the
proliferative signaling of the integrin-dependent mechanotransducers YAP/TAZ in more detail.
For many years, the co-transcriptional regulators YAP and TAZ were mainly associated with
the Hippo signaling cascade controlling organ size in vivo and contact inhibition of proliferation
in cell culture (322). More recently, YAP/TAZ also emerged as important mechanotransducers,
sensing a variety of mechanical inputs and integrating them into output signals controlling
proliferation and stem cell differentiation (116). Stiff substrates in 2D and 3D, large adhesive
areas and increased blood pressure are examples of physical parameters that induce YAP/TAZ
activity by increasing their nuclear localization (323). At the same time, active YAP/TAZ
increases the expression not only of proteins driving proliferation, but also of focal adhesion
and actin organization (305), establishing a positive feedback ensuring persistent YAP/TAZ
activation. Mechanistically, YAP/TAZ proteins were found to be inactive as long as they reside
in the cytoplasm. This is the case, when they are Ser/Thr phosphorylated, leading to the
formation of a complex with phosphoSer-binding 14-3-3 adapters (116). YAP/TAZ proteins
are phosphorylated by the large tumor suppressor gene 1 and 2 (LATS1/2) as part of the
canonical Hippo signaling pathway. Dephosphorylated YAP/TAZ instead is enriched in the
nucleus, where it binds transcription factors like TEAD1 (305). This YAP/TAZ activation is
supported by a b1 integrin-Src axis and potentially explains the proliferative effects of
b1 integrin expression (376). However, the precise mechanism of YAP/TAZ activation remains
controversial, as some groups found also integrin-independent cell adhesion on poly-L-lysine-
coated substrates to cause YAP/TAZ activation (100, 499). These reports argued that the actin
network integrity is necessary for nuclear localization of YAP/TAZ. Recent publications might
now be able to reconcile these different findings: Elosegui-Artola and colleagues (121) found
that mechanical stretching of the nuclear membrane opens nuclear pore complexes (NPCs). An
increased diameter of NPCs then allows an easier entry of YAP proteins into the nucleus. This
size-dependent mechanism of YAP transport was supported by experiments showing that
increasing the size of the YAP protein by attachment of one or two GFP reduces its nuclear
localization. The importance of mechanical force on the nucleus for YAP/TAZ activation was
also shown by Shiu, Aires and colleagues (399). Their work indicated that an actin cap,
spanning over the nucleus and thereby flattening it, applied mechanical force on the nucleus,
leading to YAP activation. This actin cap relied on b1 integrin localization in the perinuclear
region. Thus, it is evident that both b1 integrin signaling as well as actin integrity are needed
for force application on the nucleus, which then facilitates the nuclear localization of
YAP/TAZ. Apart from this mechanism, also other signaling cascades for YAP/TAZ signaling
have been introduced recently. Meng and colleagues (285) showed that focal adhesions on soft
substrates activate RAP2, leading to a deactivation of RhoA and activation of LATS1/2. As a
consequence, YAP becomes phosphorylated and remains in the cytoplasm. Thus, separate
pathways might work together to balance activation and inactivation of YAP/TAZ. However,
as mentioned in the beginning, it is important to better analyze these pathways in order to
understand the potential crosstalk with the MRTF signaling cascade. Interestingly, both
YAP/TAZ and MRTF cascades involve integrin-mediated structural linkage and signaling,
rendering these pathways fascinating examples of cellular signaling, where mechanical and
biochemical inputs are sensed and integrated by integrins and their downstream targets.
Chapter 6: The concept of mechanosensing: linking integrin-dependent cell adhesions to
signaling
Cells are in an active crosstalk with their surrounding environment. Cells integrated in a
functional tissue receive signals not only from their neighboring cells, but also sense the global
forces and metabolic state of a tissue. Although chemical signaling has highly important roles
in cellular homeostasis, also physical signals including mechanical cues are essential for proper
tissue functions. How do cells sense mechanical signals?
Integrin-mediated adhesions have a central role in cellular mechanosensing: they are physical
links between individual cells and their surrounding extracellular matrix (419). Cell-matrix
adhesions can thus be considered mechanical connectors. On the intracellular side, they are
linked to the actomyosin machinery via the cell cytoskeleton, and on the extracellular side they
are coupled to extracellular scaffolds formed by proteins such as fibronectin and collagen,
containing specific attachment sites for integrin receptors (177, 458, 493). Cell-matrix
adhesions are considered mechanosensitive, as their size, composition and signaling capacity
are known to be affected by mechanical load and substrate stiffness (123, 366).
Integrins are among the most studied mechanosensory receptors. In cellular mechanosensing, a
mechanical signal is received by a mechanoreceptor, which is capable of translating the signal
into a chemical cue (82). The chemical signal may then affect cellular processes such as gene
expression. This process is called mechanotransduction (79).
What do we know about the details of integrin-mediated mechanosensing? First of all, integrins
have several different conformations, as discussed in Chapter 2. The regulation of integrin
conformation is the first level of mechanosensing in cell adhesion (Figure 8). Although integrin
conformation can be modulated by chemical factors, the full activation of integrins requires
mechanical signals (208). However, as indicated in Chapter 2, it is still under investigation
whether mechanisms of integrin activation found in well-studied integrins can be easily
transferred to others. Therefore, we should not expect the same scheme of conformational
regulation to be applicable for all integrin family members.
The second level in integrin-mediated mechanosensing is the integrin-ligand binding (Figure
8). While protein-protein interactions typically have a decreased lifetime under mechanical
load, the bond between fibronectin and integrins a5b1 and aVb3 has been found to function as
a catch-bond, becoming stronger when force is applied (146, 233, 291).
The third level of integrin-mediated mechanosensing relates to the intracellular adapter proteins
(Figure 3, Table 1). The cytoplasmic domain of integrin acts as a ligand for several adapter
proteins, including talin (177, 228), kindlin (371), sharpin (359), tensin (156) and a-actinin
(329). These adapter proteins link integrins to the cytoskeleton, but also mediate cellular
signals. Importantly, the adapter proteins also act as mechanosensory elements (for review, see
(153, 194, 208)). The best studied example is talin, which connects to integrin via its N-terminal
head domain and to F-actin via the C-terminal rod domain (169, 228). This exposes talin to
mechanical load, facilitating conformational changes. As a result, cryptic binding sites for other
adhesion proteins become exposed and the particular adhesion site is reinforced (160). Proposed
force-regulated talin binding partners include vinculin (135, 160, 206, 247, 353, 482), DLC1
(178, 491), RIAM (170, 244, 477), and paxillin (384), but considering the size and complexity
of talin, it is likely that additional force-regulated talin interactions exist (169, 301). As
mentioned above, the situation for paxillin is unique, as it is recruited to the talin-rod by short
helical elements positioned in its flexible N-terminal domain, that show affinity towards FAK
and parvin as well as the GIT/PIX/PAK regulatory complex. On the other hand, tension-
mediated paxillin recruitment to adhesions (384) is regulated at the level of the proximal talin-
binding NPXY motif of the integrin (335), as well as the integrin-tail recruited kindlin (149,
437). While the mechano-dependent recruitment of paxillin to integrin-adhesions is still not
fully understood, it illustrates well how the connectivity of different intracellular adapter
proteins allows different signaling outputs in responses to mechanical perturbations.
Although these signaling outputs appear to create an on/off signal, it is also important that this
mechanosensing system can be used in different cellular contexts, exhibiting largely different
force regimes. Our recent study focusing on the talin rod revealed the tailoring of talin
properties to have significant effects on cellular mechanosensing (353). We found mechanically
weakened talin to decrease cellular traction force. Even more interestingly, we noticed the
recognition of extracellular matrix proteins to be altered in cells expressing mechanically
weakened talin compared to cells expressing the wild-type protein. Therefore, it appears that
mechanical signals are instrumental in controlling the environmental sensing via integrins.
The mechanically induced conformational changes in intracellular proteins contributing to cell-
matrix adhesion have been discussed in our previous review (208). We are only at the beginning
to understand the mechanoregulation of adhesion signaling at the molecular level. However,
the mechanisms are taking shape: i) opening of binding sites due to mechanical load (example:
vinculin binding sites in talin rod (115, 160, 206), ii) disappearance of binding sites due to
mechanical load (DLC1 – talin, (178, 252)), iii) phosphorylation of mechano-exposed regions
within proteins (p130Cas) (385), iv) and proteolytic cleavage of partially unfolded proteins (4).
Figure 8 aims to summarize these mechanisms. These regulatory events, combined with the
high number of components involved, makes the creation of a comprehensive model of
adhesion signaling challenging. In addition, new mechanisms still emerge as e.g. the
competition between kank2 and actin for talin binding, leading to a modulated force
transmission to integrins (420). The motor-clutch model emerged over the years as a promising
framework to explore integrin dependent mechanotransduction (73, 123). In this model,
molecular clutches link F-actin to the substrate and mechanically resist myosin-driven F-actin
retrograde flow (73). This model might in future incorporate additional features to model real
integrin-mediated adhesions more closely.
An increasing number of reports indicate that mechanotransduction on substrates of increasing
stiffness follows a sigmoidal mechanosensitivity, creating a behavioral switch at a substrate
stiffness around 5 kPa. Adhesion maturation, nuclear translocation of YAP or cell spreading
are all suppressed on substrates below 5 kPa and increase from there within a narrow stiffness
range to reach plateau levels. Roca-Cusachs and coworkers successfully linked this behavior to
the motor-clutch model (122). Importantly, this on/off mechanoswitch also implies that studies
on glass substrates, with a stiffness in the MPa range, might miss important changes in
mechanotransduction occurring around the physiologically relevant 5 kPa stiffness range.
According to the motor-clutch model, integrin-ligand affinity is a parameter that might shift the
onset of mechanotransduction from 5 kPa to softer or stiffer substrates. This also implies that
seemingly redundant integrin-ligand interactions on glass substrates might cause specific,
differential effects at physiological stiffness values. We recently showed aVb3 integrin to have
a higher affinity for vitronectin than for fibronectin, leading to differential mechanotransduction
on the respective ligands (31). We envision that the increased interest in the mechanical
regulation of integrins will lead to the discovery of further force- and stiffness-dependent
integrin-ligand interactions. At the same time, it is clear that also integrin adapters are an
intrinsic part of the mechanosensory machinery. Talin has several cryptic binding sites, that
open under mechanical stretch, and is therefore not only of interest as integrin activator, but
also as mechanosensor and mechanotransducer (see above) (170, 353, 354). Interestingly, the
mechanotransduction by talin is isoform-specific, with talin2 increasing the ability of cells to
spread on 1-2 kPa substrates compared to talin1 (26). This difference can be attributed to the
subdomains R1-R3 in the talin rod domain (indicated as yellow rectangles in Figure 6).
Interestingly, several studies found these subdomains to be relevant for mechanosensing and
force-dependent structural rearrangements. While talin is involved in integrin activation, it was
demonstrated that also an integrin inhibitor, Thy-1, modulates mechanosensing (see Figure 3E)
(136). Therefore, mechanosensing by integrins appears to rely on the proper balance between
ligand binding and unbinding.
Chapter 7: Role of integrins in viral and bacterial infections
Integrins are best known as receptors contributing to cellular attachment. However, they also
act as receptors for viruses and bacteria and are otherwise involved in pathogenic processes.
There are numerous known viruses exploiting integrins for their attachment to the cell, the virus
entry into the cell as well as endosome escape (reviewed in (201)). Many viruses display an
RGD sequence on their surface, which enables integrin binding. Adenoviruses utilize integrin
αV for virus internalization (464). Binding of the adenovirus to integrin appears to induce a
conformational change of integrin into an extended conformation; simultaneously a
conformational rearrangement is observed also in the virus capsid (261). Similarly, integrin
αVb3 has been identified as a cellular receptor mediating both the cell adhesion and entry of
Kaposi's sarcoma-associated Herpes virus into target cells (152). Another interesting group of
viruses utilizing RGD-dependent integrins are enteroviruses, being among the most common
human pathogens. Within the group of enteroviruses, only a handful of virus strains appear to
utilize integrins in cell recognition. One of them is the coxsackie virus A9 (CVA9), which
shows preferential binding to αvβ6 with a low nanomolar Kd (393). However, in this case
integrin activation might actually not promote virus internalization (393). Among other RGD-
possessing viruses, HIV utilizes α4β7 via the RGD tripeptide in the V2 loop of gp120 to infect
the cell (23), and Ebola virus appears to bind α5β1-integrin for cell entry.
Viruses do not always depend on RGD to utilize integrins in their propagation cycle. Rotavirus
infection was blocked with peptides containing the α4 integrin ligand sequences Tyr–Gly–Leu
and Ile–Asp–Ala. These peptides eliminated virus binding to α4 integrins and infectivity (171).
Another non-RGD integrin-dependent virus is Ross River virus, which appears to utilize the
collagen-binding integrin α1β1 (263). Some integrin-interacting enteroviruses do not contain
RGD-like peptides, such as echovirus 1 (41). Interestingly, this virus appears to prefer binding
to closed α2β1 integrin, and the inactivating integrin mutation E336A further enhanced this
integrin binding (213). Echovirus 1 makes a large contact with the I-domain, with MIDAS site
not being involved in binding (226). This virus  does not depend on the integrin α-subunit during
the later events of virus entry – the virus can infect cells even if the α2-tail is swapped or deleted
(40).  Notably, the binding of echovirus 1 appears to induce cellular signaling via focal adhesion
kinase (379).
The natural tendency of integrins to cluster as a response to extracellular signals is
complementary to the repetitive structure found in many virus capsids. For example,
enteroviruses are ~30 nm in diameter, and contain 60 copies of VP1-VP4 capsid proteins.
Therefore, the RGD sequences are displayed on the virus capsid almost perfectly in line with
the density of clustered integrins observed in living cells:  Changede et al. (75) reported
∼100 nm clusters containing ∼50 activated β3-integrins in the early adhesions under a wide
variety of conditions on RGD surfaces. Thus, the regular and dense arrangement of integrin
ligands on the virus particle offers a fascinating platform for the active integrin-mediated
communication between cells and viruses.
The studies of Echovirus 1 have revealed, that virus binding can lead to integrin clustering
without activation (213). Further, clustering of nonactivated integrins induces transient
phosphorylation of FAK and paxillin in a PKCα-dependent, but talin-independent manner
(379). These findings suggest that virus-induced clustering of integrins can activate FAK
without conformational integrin activation.
Coxsackievirus B3 is the most viral cause of myocarditis (for review, see (130)). Activation of
Akt during coxsackievirus B3 infection has been shown to take place through a PI3K-dependent
pathway (127). Inhibition of integrin-linked kinase (ILK) activity and expression significantly
blocked coxsackievirus B3-triggered Akt phosphorylation on Ser473 without effect on Thr308
phosphorylation. As a consequence, ILK inhibition lead to a significant decline in
coxsackievirus B3 RNA transcription, viral protein synthesis, and virus progeny release.
Integrins are involved also in bacterial infections, and the following examples provide some
insights into the mechanisms. A more extensive summary of bacterial species engaging
integrins within the infection cycle can be found in a review by Hauck et al. (186).
Shigella bacteria cause shigellosis, a common intestinal infection leading to diarrhea and fever.
Using CHO cells expressing integrin subunits, Watarai et al. showed that integrin α5b1
promotes the entry of the Shigella flexneri bacteria (455). They demonstrated IpaB, IpaC and
IpaD proteins to bind to α5b1. Interestingly, Shigella appears to utilize also other components
of the cell adhesion complex during its invasion, including vinculin (326) and ILK (224).
Staphylococcus aureus is a common cause for respiratory infections. Most clinical isolates of
S. aureus express the fibronectin-binding proteins FnBP-A and FnBP-A (330). Binding of
fibronectin by FnBPs is essential for the bacterial invasion, with fibronectin functioning as a
bridging molecule linking FnBP to integrin α5β1 (reviewed in (186)). This leads to the active
intake of the bacteria, which does not require other bacterial factors, since even FnBP-coated
polystyrene beads are internalized by cells (405).
Invasins are a class of bacterial proteins associated with the penetration of bacteria into cells.
Isberg et al. showed that α3β1, α4β1, α5β1, and α6β1 all bind the Yersinia pseudotuberculosis
invasin protein (210). The integrin-binding domain was mapped to a 192-aa C-terminal region
of invasin that does not contain any RGD sequence (251). This integrin-binding domain was
found sufficient to allow bacterial entry into mammalian cells (358). Later, beads coated with
a larger invasin derivative comprising the C‐terminal 497 amino acids were found to be
internalized more efficiently than those bearing only 197 C-terminal residues. This seemed to
be explained by the homomultimerization of the immobilized invasin fragment (106),
suggesting a role of integrin clustering also in bacterial invasion.
The last example of integrin-bacteria-interaction demonstrates how bacterial cells can modulate
tissue structure to support bacterial colonization. In some human tissues, the turnover rate of
cells can be high, and e.g. the intestinal epithelium self-renewal is completed within 2–3 days
(342). Slowing down this epithelial turnover can support bacterial colonization during an
infection (212). Shigella flexneri can reinforce host cell adherence to the basal membrane via
ILK (224). The interaction between ILK and the effector protein OspE increases cell surface
levels of b1 integrin and suppresses phosphorylation of focal adhesion kinase and paxillin. As
a result, the reduced adhesion turnover and suppressed detachment of infected cells enables
Shigella to colonize the epithelium. In a similar fashion, some bacteria such as N. gonorrhoeae
can bind to human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs),
promoting enhanced host cell adhesion via integrin b1 activation (297).
In summary, integrins are important mediators of viral and bacterial infections, and integrin-
mediated attachment, internalization as well as control over tissue integrity are central
mechanisms in pathogenic processes. One may thus ask if integrins are employed more
frequently as receptors for pathogens than other cell surface proteins. This is not straightforward
to address: Although integrins are widely utilized by viruses and bacteria (280, 413), also
numerous other known viral receptors are known (173). Potentially the intense study of
integrins has lead to their frequent identification as virus receptors. In any case, it appears
remarkable, that viruses, having a highly variable structure and shape, can exploit integrins in
cell recognition. One such example is the utilization of integrins by adenoviruses and
enteroviruses, two different classes of viruses with different evolutionary origin, showing both
five integrin binding sites located in pentagonic assembly with spacing of ~60Å (reviewed by
Stewart & Nemerow (413)). We therefore speculate that integrin clustering and integrin
activation are suitable cellular mechanisms for the exploitation by infectious agents, and that
the integrin-pathogen interactions thus offer potential targets for development of novel drugs.
Chapter 8: Integrins and diseases
Integrins are central for the integrity of the tissues, cellular adhesion and cell-matrix
interactions, and it is therefore not surprising that several diseases are associated with defects
in integrins. These integrin-related diseases are an active target for drug development, and a
search with the term “integrin” revealed 151 studies in ClinicalTrials.gov, reflecting the
importance of this research field. A significant portion of these studies (~30%) are focusing on
integrin-targeting drugs. The first integrin-targeting drug entering the market 1994 was
Abciximab (ReoPro), a 47 kDa Fab fragment against αIIbβ3 based on the monoclonal antibody
developed by Coller et al. 1983 (91). This antibody also binds αvβ3 (430) and αMβ2 (403); it
is used to prevent blood clots during the opening of blood vessels in the heart. Eptifibatide
(Integrilin) is a cyclic heptapeptide derived from a barbourin protein found in the venom of the
southeastern pygmy rattlesnake. This peptide targets αIIbβ3 and is used to reduce the risk of
acute cardiac ischemic events (183, 435). It was launched in Europe 1999 and in USA 1998.
Tirofiban (Aggrastat) is small molecule inhibitor for αIIbβ3. It was approved in USA 2000 and
in Europe 1999 for the treatment of acute coronary syndrome. Natalizumab (Tysabri) is a
humanized monoclonal antibody against α4-integrin used in the treatment of multiple sclerosis
(339) and Crohn's disease (167). Natalizumab is thought to prevent immune cells from crossing
blood vessel walls to reach the affected organs. The most recent integrin-targeted therapeutic
antibody accepted for clinical use is Vedolizumab (Entyvio), which is a humanized monoclonal
antibody specifically binding to the α4b7 integrin and blocking the interaction of α4b7 integrin
with mucosal addressin cell adhesion molecule-1 (407). This leads to inhibition of the migration
of memory T-lymphocytes across the endothelium into inflamed gastrointestinal tissue (372).
Vedolizumab is approved for treating patients with ulcerative colitis or Crohn’s disease.
The following paragraphs provide insights into the importance of integrins and integrin
activation in various diseases.
Integrins and skin diseases
Integrins are important for the integrity of the skin. Experiments with genetically manipulated
mice have shown that deletion of α6 or β4 leads to disappearance of hemidesmosomes and the
impairment of the epidermal adhesion to the underlying basement membrane (114, 155, 307).
Even modest mechanical stress causes peeling of the epidermis from its underlying tissue in
these animals. In humans the equivalent disease is known as junctional epidermolysis bullosa,
and the associated genetic factors are reviewed in (185).
Mice deficient in α3 integrin have only a mild skin phenotype: the epidermis of α3 integrin-
deficient mice has normal morphology and other characteristics (111, 192, 235). Also the
hemidesmosomes of α3 integrin-deficient mice appear intact, and most regions of the basal
membrane are coherent. The only defects observed in these animals are microblisters in the
limb skin regions due to ruptures within the basal membrane.
As b1 integrin is essential for mouse development (132, 412), the role of β1 in skin epithelium
has been studied using conditional knockout technology (56, 352). Mice with keratinocyte-
specific knockouts for β1 integrin exhibit severe skin blistering and hair defects (352). In detail,
a massive failure of basement membrane organization was observed, hemidesmosomes were
instable and hair follicle keratinocytes failed to remodel the basement membrane. Also,
Brakebusch et al. generated mice with a keratinocyte-restricted deletion of the β1 integrin using
the cre-loxP method (56). This resulted in hair loss and hair follicle abnormalities, and the
epidermis of the skin became hyperthickened. The loss of β1 also caused a reduced α6β4
expression in basal keratinocytes and a decreased number of hemidesmosomes. Moreover,
disruption of the basement membrane and blister formation were observed at the dermal-
epidermal junction.
Integrins have also been a target for drug development for skin diseases. Efalizumab (Raptiva)
is a recombinant humanized monoclonal antibody designed to treat autoimmune diseases (462),
that was originally authorized for the treatment of psoriasis by EMEA 2004 and FDA 2003
(168). Efalizumab binds to the integrin αL subunit of the αLβ2 integrin specific for leukocytes
(189). However, the marketing of efalizumab was suspended 2009 due to side effects such as
Guillain-Barré and Miller-Fisher syndromes, encephalitis, encephalopathy, meningitis, sepsis
and opportunistic infections.
While integrin activation by intracellular proteins is discussed elsewhere in this review, in the
context of skin diseases, it is relevant to pinpoint the connection between kindlin and skin
diseases. The best-known disease associated with kindlins is Kindler syndrome, involving the
loss of kindlin-1 expression in epidermis (402). Gene knockout of Fermt1, the gene encoding
kindlin-1, in mice caused skin atrophy and lethal intestinal epithelial dysfunction (444).
Cancer
Integrins have a central role in cancer, as reviewed previously (107, 374), and it is not possible
to give a comprehensive overview within this article. Instead, we provide here selected
examples of the importance of integrin activation in cancer.
Felding-Habermann et al. (134) demonstrated activated integrin avb3 mutant D723R to support
tumor cell arrest in the circulation through the interaction with platelets. This activated αvb3
was found to be expressed by metastatic human breast cancer cells, leading to metastatic
lesions. Expression of the constitutively activated integrin mutant αvb3-D723R promoted
metastasis in a mouse model. These results support a model where breast cancer cells can
exhibit a platelet-interactive and metastatic phenotype controlled by the activation of integrin
αvb3. Beside this mechanism, αvb3 integrin might have additional and parallel modes of action
supporting cancer progression and metastasis. Several studies indicated that αvb3 integrin and
VEGF receptor signaling act synergistically to promote angiogenesis (101, 274), an important
part of tumor progression. This link between αvb3 integrin and VEGF signalling motivated
clinical trials with Cilengitide, a specific inhibitor of αvb3 and αvb5 integrin. Also glioblastoma
express avb3 integrin, in contrast to the healthy surrounding tissue, making αvb3 integrin
inhibition a promising strategy for the treatment of this cancer. Accordingly, orphan designation
for Cilengitide (EU/3/03/184) was granted by the European Commission on 14 January 2004
to Merck KGaA, Germany, for the treatment of glioma. Unfortunately, the drug was later
removed from the market, as the phase 3 study showed no positive effect in glioblastoma
treatment (415). A mechanism explaining the failure of Cilengitide in this clinical trial is still
missing, although it was recognized later on that a low dosing of Cilengitide activates
angiogenesis in mice rather than preventing it (362). This surprising effect might be explained
by systemic effects, but the partial agonism of high-affinity integrin inhibitors like Cilengitide
might still challenge this therapeutic strategy. In fact, we recently showed that the correlation
of the different ectodomain conformations of integrins with immobilized ligand binding is still
challenging. We revealed that αvb3 integrin binds vitronectin in the extended-closed
conformation, but fibronectin only in the extended-open conformation (31). Thus, rational drug
design could benefit from further research efforts focusing on integrin-ligand interactions that
take into account the conformational flexibility of the integrin ectodomain. Furthermore, this
research should be performed appreciating the non-redundancy of these interactions.
Chronic myeloproliferative neoplasia comprises several sub-entities, including polycythemia
vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PMF) and others (436).
Chronic myeloproliferative neoplasia caused by the V617F mutant of Janus kinase 2 (JAK2)
commonly displays abnormal integrin expression on platelets, erythrocytes and leukocytes
(118). A recent study found JAK2-V617F to trigger constitutive activation of the integrin
inside-out signaling molecule Rap1, resulting in translocation to the cell membrane (118). In
transgenic mice expressing this JAK2-V617F protein in hematopoietic cells JAK2+/VF
granulocytes showed increased binding of 9EG7 antibody, indicating the conformational
activation of β1 integrins. Moreover, increased expression of both β1 and β2 integrins was
observed (118). The researchers also demonstrated the neutralizing anti–α4 (anti-VLA-4) and
anti–β2 integrin antibodies to suppress the pathologic thrombosis observed in JAK2+/VF mice.
Additionally, the aberrant homing of JAK2+/VF leukocytes to the spleen was inhibited by the
neutralizing anti-β2 antibodies or alternatively pharmacologic inhibition of Rap1. These
findings suggest that JAK2-V617F, a mutation commonly associated with myeloproliferative
disorders (214), leads to integrin activation, promoting pathologic thrombosis and abnormal
trafficking of leukocytes to the spleen (118).
Cancer-associated fibroblasts (CAFs) are the most abundant cells in a tumor (216). Attieh et al.
found that CAFs isolated from the tumor of colon cancer patients secrete and assemble
fibronectin more efficiently compared to noncancer-associated fibroblasts from the neighboring
healthy tissue (25). Importantly, the amounts of secreted and assembled fibronectin correlated
with the invasion index of the tumor. This study suggests mechanical signals to be important
for CAF-mediated cancer cell invasion, as they induce fibronectin assembly. The authors
propose that contractility of CAFs is necessary for downstream activation of the integrin-αvβ3
and assembly of fibronectin puncta. α5β1 becomes critical only at later stages of fibronectin
assembly. In summary, Attieh et al. (25) revealed that fibronectin-depositing CAFs enable
cancer cells to invade the matrix and this process is independent of matrix metalloproteinases.
LAD-III: Kindlin-3 is essential for proper integrin activation
A rare autosomal leukocyte adhesion deficiency syndrome called LAD-III is characterized by
severe bleeding and impaired adhesion of leukocytes to inflamed endothelia. A hallmark of this
recessive disease is the impaired activation of β1, β2 and β3 integrins on platelets and
leukocytes (12).
Malinin et al. described a kindlin-3 point mutation causing serious bleeding, frequent infections
and osteopetrosis at an early age (277). They found the symptoms to be caused by an integrin
activation defect in hematopoietic cells, including platelets and leukocytes. The lymphocyte
cell line established from the patient was phenotypically rescued by expression of wild-type
kindlin-3, proving the association of the disease to the defective kindlin-3. The inactivation of
kindlin-3 was caused by a point mutation creating a premature stop codon at the amino acid
position 16. Importantly, all the clinical symptoms of the subjects were resolved by an allogenic
bone marrow transplantation. Also another study by Svensson et al. (421) found a link between
kindlin-3 and LAD-III,  identifying two independent mutations causing decreased KINDLIN3
messenger RNA levels and loss of protein expression.
During the last years it has become evident that integrins are not only activated by talin, but
also in coordination with kindlin binding to the second NxxY motif (335). As kindlin-3 is
expressed exclusively in hematopoietic cells, it is clear now that LAD-III is caused by
insufficient integrin activation due to the lacking kindlin contribution. Moser et al. 2008 (295)
found kindlin-3 to interact with β1 and β3 integrin tails both in the presence and absence of
talin-1, with the F3 subdomain of kindlin-3 being sufficient for this direct interaction. Later,
Moser et al. 2009 (294) showed that kindlin-3 binds the cytoplasmic domain of β2 integrin.
They proposed kindlin-3 to be essential for neutrophil adhesion and spreading on β2 integrin-
dependent ligands such as intercellular adhesion molecule-1 and the complement C3 activation
product iC3b.
Autosomal dominant polycystic kidney disease
Integrins are highly important for the kidney development, and a comprehensive overview on
the phenotypes associated with various integrin mutations in mouse models has been provided
by Mathew et al. (282).
Autosomal dominant polycystic kidney disease (ADPKD) is a disorder involving the
development of bilateral renal cysts, accumulation of extracellular matrix and tubulointerstitial
fibrosis (440). The disease is caused by the mutation of the PKD1 or PKD2 genes encoding
polycystin-1 (PC1) or polycystin-2 (PC2), respectively (184). Interestingly, the cystic epithelia
express higher levels of integrins (246).
A recent study (246) showed that depletion of PC1 in immortalized renal collecting duct cells
elevated the levels of integrin-β1 and fibronectin and displayed increased integrin-mediated
signaling in the presence of Mn2+ compared to wild-type cells. Conditional inactivation of
integrin-β1 in collecting ducts of mice resulted in a dramatic inhibition of Pkd1-dependent
cystogenesis with a concomitant suppression of fibrosis and preservation of normal renal
function. These results suggest functional integrin-β1 to be required for the early events leading
to renal cystogenesis in ADPKD.
Integrins and liver diseases
Chronic injury in liver is characterized by intense production of collagens and other ECM
components accompanied with their decelerated degradation, leading to net matrix
accumulation (reviewed in (389)). Several clinical studies have found changes in integrin
expression to be associated with chronic liver diseases. Nejjari et al. (306) studied patients with
chronic hepatitis C and found an increase in b1 labeling intensity in 83 out of 94 patients
(88.2%). Moreover, also expression of α1, α5 and α6 integrins were pronounced (306). Popov
et al. (340) extracted total RNA from explant livers of patients undergoing liver transplantation.
They found β6 integrin mRNA transcript levels to be significantly elevated in patients with
chronic hepatitis B and C, primary biliary cirrhosis, primary sclerosing cholangitis and alcohol-
induced liver injury. This suggests integrin overexpression to be an etiology-independent factor
associated with liver fibrosis.
Atherosclerosis
Atherosclerosis is a chronic inflammatory disease involving accumulation of lipids, cell debris
and extracellular matrix proteins as well as monocyte-derived macrophages at the inflamed
vascular wall. The M1/M2 macrophage ratio can be considered a determinant of plaque stability
(reviewed in (325)). A study by Cho et al. revealed that M1 macrophages are exclusively found
in plaques of symptomatic patients and elevated in unstable plaques (87). Aziz et al. (27) studied
the role of αDb2 integrin in atherosclerosis using both mouse and human samples. In this study
the retention of macrophages was linked to a significant upregulation of integrin αDb2 in M1
macrophages in vitro and in macrophages in atherosclerotic lesions. The findings suggest that
αDb2 contributes to the development of chronic inflammation via regulation of macrophage
migration. Interestingly, our study focusing on human arterial plaques showed upregulation of
integrin b2, while all other studied integrins (ITGA1, ITGAV, ITGB3, ITGB5) were
downregulated (315).
Integrins and smoking
Pulmonary emphysema, largely attributable to tobacco smoke exposure, is a worldwide
challenge. Morris et al. observed elevated expression of matrix metalloproteinase 12 in mice
lacking the integrin avb6, that developed progressive spontaneous emphysema. The
emphysema was prevented by transgenic b6 integrin expression, which, however, was
dependent on the ability of b6 to bind and activate latent TGF-b. Importantly, the pathological
characteristics of mice lacking avb6 integrin resemble those observed in young cigarette
smokers (310).
Overbeek et al. (319) studied the effect of cigarette smoke on neutrophil migration and β2-
integrin activation. CD11b-expressing neutrophils appeared in the lungs of mice after exposure
to cigarette smoke for 5 days. To interpret this finding further, they exposed freshly isolated
human neutrophils to cigarette smoke extract (CSE). CSE activated αMβ2 on the neutrophils,
leading to firm adhesion to fibrinogen. In response to CSE the neutrophils transmigrated
through endothelium via the activation of β2-integrins, and the functional block of CD11b and
CD18 decreased this transmigration.
Although e-cigarettes could be considered a “healthy” choice compared to traditional cigarettes,
a recent study revealed that platelets from e-cigarette-exposed mice are hyperactive, show
enhanced aggregation and granule secretion. Importantly, also these platelets showed increased
activation of the αIIbβ3 integrin (351).
Chapter 9: Integrins and TGF-b activation at the onset of fibrosis
In recent years cancer cells were demonstrated to cooperate extensively with cancer-associated
fibroblasts, shaping the tumor microenvironment (67). These CAFs rearrange the tumor-
surrounding ECM, increase its stiffness and promote cancer cell invasion (25, 67). This
pathological ECM stiffening, called fibrosis, is not restricted to cancer, but rather constitutes a
pathology of its own. In a simplified way fibrosis can be described as excessive scar formation.
While scars preserve the mechanical integrity of the tissue, they fail to support normal organ
function, such as gas exchange in the lung or the beating of the heart. Ultimately fibrosis can
lead to organ failure and death and is estimated to contribute to more than 40% of deaths in the
developed world (468). The onset of fibrosis is characterized by the transformation of cells into
contractile myofibroblasts, mediated by signaling molecules of the transforming growth
factor b (TGF-b) family (190). Interestingly, cells do not secrete TGF-b in a soluble form, but
rather as a complex with the latency associated peptide (LAP). This LAP/TGF-b complex is
anchored to the ECM via latent TGF-b binding protein (LTBP), preventing TGF-b from
binding to its receptor (190). The release of TGF-b from this complex requires the binding of
integrins to an RGD sequence in LAP and mechanical load on the ECM-(LAP/TGF-b)-integrin
axis (299). In fact, replacing the RGD sequence in LAP by RGE prevents integrin binding to
LAP and in mice leads to a phenotype comparable to a complete TGF-b knockout (481). This
highlights the importance of integrin binding in the process of TGF-b release and subsequent
transformation of cells into myofibroblasts. For the same reasons, integrins are also interesting
drug targets for the treatment of fibrosis, where complete TGF-b inhibition causes too many
adverse side effects (240).
A survey of the literature suggests that the complete group of αV integrins, including αVb1,
αVb3, αVb5, αVb6 and αVb8, binds to LAP. However, TGF-b activation appears to be
mediated only by αVb8 integrin and especially αVb6 integrin (368), while a recent work
indicates that also αVb1 integrin might be relevant (361). Whether these integrins compensate
each other or whether they act in a tissue- and development-specific context remains to be
explored. Dong and colleagues (113) published structural data for the binding of LAP/TGF-b
to aVb6 integrin and revealed that the binding interface of aVb6 integrin and LAP/TGF-b is
highly interdigitated and larger than other integrin-ligand interfaces. This spatial arrangement
of integrin and ligand might help to ensure the proper alignment of the force with the TGF-b
activation axis, when mechanical load is applied to the complex. Additionally, the unusually
large interface between aVb6 integrin and LAP/TGF-b might help to increase the mechanical
stability of the integrin-ligand bond. It also explains why b3 and b5 integrins cannot be
receptors for the LAP/TGF-b complex. Thus, the binding of aVb6 integrin and LAP/TGF-b
offers an example of a specific structural and molecular arrangement supporting biological
functions with consequences for the complete organism.
The importance of integrins in fibrosis is not limited to TGF-b activation. The interplay of
physical and biochemical parameters in fibrosis increased the interest in this pathology as a
promising in vivo example for the relevance of mechanobiology. Many healthy tissues have a
stiffness (measured as Young’s modulus E) below 5 kPa, but exceed this value during fibrosis.
For example, lung tissue switches from 2 kPa in a healthy state up to 17 kPa in fibrosis, while
liver stiffness increases from below 1 kPa and less up to 12 kPa and more (461).
As discussed in Chapter 6, mechanotransduction for many processes is regulated by an on/off-
mechanoswitch that is triggered around a substrate stiffness of 5 kPa. Therefore, fibrotic tissue
stiffness above 5 kPa might cause a constant on-switch of YAP/TAZ-dependent proliferation,
contributing to the positive feedback loop of YAP activation and tissue stiffening (67).
Chapter 10: Outlook and perspectives
Starting with Abercrombie (1), the research of integrins and integrin-mediated adhesions has a
history of 40 years. We are not aware of many other fields in biology that attracted so constant
interest for such a long time. One reason might be the technical accessibility of integrin-
mediated adhesions, making it an easy target for the newest microscopic techniques or
proteomic studies. At the same time, integrins and cell matrix adhesions proved repetitively
that they are not passive ‘gluing’ structures fixing cells to the ECM. Instead, they are tightly
regulated, integrating many intracellular and extracellular signals to create very diverse cellular
processes ranging from adhesion, migration or ECM organization to proliferation. The
multitudes of direct integrin-adapter interactions in the cell (Table 1 and Figure 4) reflect these
diverse integrin functions. This complexity of integrin-mediated signaling clearly justified the
ongoing interest in cell adhesion over the years. Whether the current interest in integrins and
cell adhesions will last for another 40 years is hard to predict. But we feel that there are plenty
of open questions remaining:
Integrin-mediated mechanosensing
We highlighted already the relevance of mechanical integrin regulation (Chapter 6) additional
to the established influence of biochemical signaling. This is currently a vibrating area of
research, and we expect the mechanobiology of cell adhesions to also have a profound impact
on the development of integrin-targeted therapies (Chapter 8). The increasing number of
examples for mechanical regulation of integrin conformation and thereby integrin activation
(Chapter 2) imply, that this mechanical regulation has to be considered in the development of
drugs targeting cell adhesion. For example, a drug binding to only one integrin conformation
or a drug leading to allosteric head-piece opening may be more difficult to use in the clinic than
a drug that acts as an integrin antagonist, blocking the conformation of integrins in the extended
closed conformation upon binding (5). Alternatively, mechanical forces on integrins can affect
its conformation and by this the binding affinity of the drug. Such an example has been
documented for imatinib (Gleevec), which suppressed c-Kit kinase activity when stimulated
with a soluble Kit-ligand, but failed to inhibit c-Kit signaling mediated by a mechanically
anchored Kit-ligand (424). We assume that mechanical forces on the ligand-bound c-Kit
rendered the binding pocket unavailable for imatinib, in contrast to the situation with soluble
Kit-ligand, where the competitive inhibitor imatinib could bind and inhibit, c-Kit. Other
examples include bacterial adhesins, giving rise to fibronectin-binding peptides that recognize
only relaxed fibronectin fibrils (20). Such a load-dependent binding might be disadvantageous
in a therapy, limiting the activity of the drug or antibody. At the same time, it is clear that
integrins are a promising and powerful drug target, with successful therapies for thrombosis
and emerging therapies for multiple sclerosis and other immune system-related diseases
existing (165). In fact, immune suppression by targeting a4b1 integrin (natalizumab) or aLb2
integrin (efalizumab) is too effective, causing progressive multifocal leukoencephalopathy by
activating the human polyomavirus JVC in some patients (276). However, conformation-
and/or mechanical load-specific therapies might one day offer a less toxic, but more selective
approach in therapies targeting cell adhesion.
Integrins and therapies
The safety and ultimate clinical success of integrin-targeting drugs remains still to be evaluated
(Chapter 8). Nevertheless, it is indisputable that the failure of the aVb3 integrin inhibitor
cilengitide in phase III trials (including Merck giving up on further trials for this inhibitor)
dampened the enthusiasm about chemotherapies targeting integrins. Are there more general,
fundamental problems with drugs targeting integrins? Above, we mentioned the influence of
mechanical forces on the integrin-ligand binding pocket and potential consequences for drug
development. However, we also tried to raise awareness for the specificity of integrins, their
ligands, and their adapters throughout this review. In other words, we might just not know
enough about integrins for a faithful generalization. Structure-function relationship (Chapter
2), RIAM-dependent vs. -independent integrin activation (Chapter 3), reticular adhesions vs.
focal adhesions (Chapter 3), or the relevance of aVb1 integrin in fibrosis (Chapter 9) are
examples where established findings were recently challenged. Kindlin as integrin activator is
much less understood than talin, kank is still emerging as potentially important adapter, and all
of them have isoforms that withstood evolutionary selection while we tend to ignore them to
keep things simple. But maybe we still have to add more trees before we can clearly see the
forest. In the end, integrin targeting therapies are most successful in intensively studied systems
such as platelets and integrins in the immune system.
Cell adhesion and metabolism
The research of metabolism seems to expand very rapidly at the moment, and it is linked to an
increasing number of topics including integrin research and the interplay between cell
metabolism and cell adhesion. This is strikingly demonstrated by the effects of diabetes on
ECM and integrin organization (21). Interestingly, the metabolic sensors mTOR (355) and
AMPK (156) are both shown to act via tensins on fibrillar adhesions and endocytosis, thus
organizing the ECM (Chapter 3). This link between integrin-dependent ECM organization and
metabolism might also explain the correlation of fibrosis (Chapter 9) and obesity. Moreover,
there are first indications that integrin and integrin adapters are targets of metabolism-
dependent posttranslational modifications like acetylation (89, 460), potentially establishing a
close link between metabolism and cell adhesion.
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Figures and figure legends
Figure 1 Integrins, their ligands, and cellular distribution.
As reviewed by Hynes (129), integrins are organized in 24 different heterodimers, indicated by
the link between a- and b-subunits in the figure. Integrins can be classified by structural
features, their ligands, and their tissue and cellular expression. Based on these criteria, we
grouped integrins into nine classes indicated by the color of their background. Typical cell types
expressing the respective integrins are mentioned, as well as common ligands for these
integrins. We also highlighted integrins with an a-I domain (I; purple circle), those binding to
RGD ligands (RGD; red square), and those with changes to the conserved GFFKR sequence in
the membrane-proximal part of the a-subunit (black triangle indicates integrins with sequence
deviating from CGFFKR). The integrin cartoon in the lower part of the figure gives an overview
about the integrin structure and is reused in the following figures. It also indicates the location
of the aI domain and the GFFKR sequence in the respective integrins. Please note that aI
domain integrins bind ligands (e.g. collagen) via this I-domain, while other integrins bind
ligands (e.g. fibronectin) in binding pockets formed by both a- and b-subunits.
Figure 2 Structural features of the integrin heterodimer.
Integrins consist of a- and b-subunits, and both of the subunits are membrane anchored. The
integrin subunits non-covalently associate in the extracellular domain via the insertion of a
conserved lysine residue of the b-I-like domain (blue) into the aromatic core of the a-propeller
domain (red) (upper left; respective amino acids are indicated by their structure instead of a
cartoon-like representation), locking the subunits tightly together. There are also more dynamic
interactions occurring at the transmembrane (outer and inner membrane clasp) and
juxtamembrane regions (inner membrane clasp) of the two subunits. Conserved glycine-motifs
in both transmembrane domains allow the tight association of the transmembrane domains at
the outer membrane clasp, while the inner membrane clasp is stabilized by aromatic
interactions. Sequence on the lower right: a-subunit: FF; b-subunit: W) and a juxtamembrane
salt bridge. Sequence on the lower right: a-subunit: R; b-subunit: D); both interactions are
highlighted on the lower left by showing the respective structures of the amino acids.
The cytoplasmic domains contain binding epitopes for a number of proteins, discussed further
in Figure 4. The interface between the a-propeller in the integrin head piece and metal ions
bound to the b-I-like domain, form a binding site for integrin ligands such as RGD (upper right
zoom-in; metal ions from left to right: SyMBS (synergistic metal binding site), MIDAS (metal
ion-dependent adhesion site), ADMIDAS (adjacent MIDAS)). In contrast, integrins with an a-
I domain in the a-subunit bind their ligand only with the a-I domain (purple circle in the central
cartoon; see also Figure 1). Ligand affinity is modulated by the coordination of the metal ions
that includes amino acids of the integrin as well as the ligand (see Fig. 3C for details). Structural
information regarding the lysine insertion into the a-propeller is from PDB 3VI4 (a5b1 integrin
(302)), for the MIDAS site from PDB 3ZE2 (aIIbb3 integrin (501)), and for the transmembrane
domains from PDB 2K9J (aIIbb3 integrin (242)).
Figure 3 Ligand-induced conformational changes and sequence specific variations in the
integrin ectodomain.
Ligne claire drawing of a prototypical integrin headpiece and mechanisms of atomic (C),
small (A,B,D) and large (E) scale conformational changes. A) Closed, ligand-free state of the
integrin headpiece stabilized by the ADMIDAS (adjacent to MIDAS; see also Figure 2) Ca2+
ion, linking the N-terminal end of the “broken” or “bent” a1/a1’-helix with the b6-a7helix
loop, by coordination (large, bold arrows). In the closed conformation/state, the a7-helix
(piston) is tethering the hybrid-domain to form a small bI-like/hybrid-domain angle.
Experimental N-glycosylation at N303 (b3) has been used to prevent the formation of the
closed integrin head-piece (90, 272). The closed head-piece conformation is further
maintained by flexible associations of the lower leg domains (see E) by the membrane clasp,
as indicated by a spring. Residues relevant for integrin isoform specific RGD-ligand binding
of the a-propeller domain are shown by arrows (see also Figure 5). Conserved residues
involved in MIDAS (metal ion depending adhesion site) coordination are labeled according to
human b3 (small arrows). Ligand binding specificity in the b-chain is achieved by the
specificity-determining loop 2 (SDL2) and residue Y122 (small arrows). For example, SDL2
makes contact with the internal ligand “IEGT” in aI-domain containing integrins (D)(aXb2;
(391)), with MadCAM in a4b7 (489), or with the RGDL motif in the TGF-b binding
integrins avb6 and avb8, while simultaneously avoiding steric clashes with TGF-b due to an
Ala-residue at the Y122 position (113, 321)(see Fig. 5B). Integrin headpiece opening is
induced by the Asp-residue binding of RGD at the MIDAS site, which leads to the movement
of the ADMIDAS ion and a1-helix straightening towards the MIDAS Mg2+ ion (large arrow),
as well as progressively stronger association of the Arg-side chain of the RGD peptide with
the a-domain. ADMIDAS, S123 side-chain and backbone movement towards the MIDAS ion
are linked to a rotation of the carboxyl-group of the RGD, Asp-residue and stabilization by H-
bonds (thick dotted green lines in C). Due to this movement, the b6-a7 loop detaches from
the ADMIDAS  Ca2+ ion and induces the piston-like downward shift of the a7-helix, pushing
the hybrid domain outwards. The hybrid domain swing-out and opening of the interdomain
angle is facilitated by a flexible domain connection at the N-terminus of the b1-strand of the
b-I-like domain. RGD-ligand binding and cytoplasmic adapter-mediated link to the actin
cytoskeleton result in a tension vector parallel to the hybrid-domain (see also E). C) Close-up
view of the SyMBS , MIDAS, and ADMIDAS coordination and their changes during integrin
opening. In the closed state, the incoming RGD-ligand coordinates with the MIDAS ion,
forming a single H-bond with the backbone amine of Y122. Rotation of the carboxyl side-
chain establishes additional H-bonds that progressively induce the movement of S123 and
backbone-associated ADMIDAS Ca2+ ion to directly coordinate MIDAS or D251,
respectively. These changes in MIDAS and ADMIDAS coordination further stabilize RGD-
ligand coordination as well as the detachment of the b6-a7-loop to induce a7-helix pistoning.
D) I-domain-containing integrins show a similar mechanisms of acidic residue binding at the
MIDAS (internal ligand peptide: IEGT), but an additional hydrophobic interaction at a
preceding Ile-residue ((391), PDB: 4NEN). A similar binding mode, centered around a
glutamic acid or aspartic acid residue, has been proposed for laminin-binding integrins (348,
429), as well as for a4b1-binding of the LDV-motif in the IIICS alternatively spliced domain
of fibronectin, and the I/L-D-T/S consensus sequence in MAdCAM-1 and VCAM-1 binding
to a4b1/7 (489). However, and in contrast to RGD-binding integrins, the binding groove of
a4-binding integrins is vertical, binding parallel to the smooth, ligand-facing a-propeller
surface for the latter integrins (D). E) Ligand-induced conformational changes in the integrin
head-piece are proposed to be associated with the head-piece opening of the integrin. The
ligand can be external (e.g. fibronectin) or, in the case of the aI-domain containing integrins,
be the aI-domain serving as an internal ligand for the integrin headpiece (289). However,
physiological ligands might also be recognized in cis, as proposed for Thy-1 (136) or b2
integrins and ICAM (131). Alternatively, Adair et al. have demonstrated FN type III9-10
binding to the bent conformation of avb3 (3). For a5b1, the synergy site on the a-propeller
surface enhances the FN on-rate (302). A recent survey of integrin ectodomain conformations
by electron microscopy demonstrated that the b1-class of integrins are more extended in the
inactive state compared to avb3 (289).  This, however, underlines the importance of the
intracellular integrin adapters, as they can either prevent integrin activation, like in the case of
sharpin, filamin and LCP1 (264, 359, 441), or induce leg separation and integrin extension
(484), that should subsequently facilitate ligand binding, and full head-piece opening. Note
that (a) to (c) indicate a temporal order. An ultimate regulation of the open head-piece
conformation could be achieved by mechanical tension, changing the conformational
equilibrium of the bound integrins (31, 347, 422).
Figure 4 Structural features of integrin ligand binding – intracellular ligands.
Cytoplasmic integrin tails comprise only a short part of the complete integrin, but interact
with a wide number of adapters (or intracellular ligands; see also Table 1). Here, structures of
integrins binding to cytoplasmic adapters are shown together with the amino acid sequence of
integrins highlighted in red (a-subunit) or blue (b-subunit), indicating the involved amino
acids in the binding of the respective adapter. Integrin inhibitors like ICAP or Filamin
compete with integrin activators like kindlin or talin for binding to the same domains of the
cytoplasmic integrin tail (compare structure A to structure E and structure B to structure D).
Kindlin binding arranges the membrane-distal part of the b-integrin tail, potentially priming
the integrin for talin binding (30). Talin binding to the membrane-proximal part facilitates the
separation of a- and b-subunit (380) and thereby integrin activation. The respective sequences
in the b-subunit (indicated with blue letters) are highly conserved among integrins. Inactive
integrins are stabilized by the interaction of a conserved sequence in the transmembrane part
of the a-subunit (GFFKR) with the b-subunit. Integrin inactivation can occur by Tyr-
phosphorylation of the NPXY-motifs, or alternatively by Ser/Thr-phosphorylation of the
inter-NPXY-region, which reduce talin and kindlin association (14, 45), while allowing
regulatory and recycling adapter recruitment to the integrin receptors. Alternatively, integrins
can be internalized bound to their extracellular, but proteolytically fragmented ligands (see
Chapter 3; (142, 293, 328)). A) ICAP1 + b1 integrin: PDB 4DX9 (267). B) Filamin-A +
αIIbb3 integrin: PDB 2MTP (264). C) Src + b3 integrin: PDB 4HXJ (469). D) Talin2 + b1D
integrin: PDB 3G9W (16). E) Kindlin2 + b1A integrin: PDB 5XQ0 (253). F) 14-3-3ζ + b2
integrin (cyan and blue): PDB 2V7D (428); 14-3-3ζ + α4 integrin (light brown and red): PDB
4HKC (48). G) Shc + b3 integrin: PDB 2L1C (108). H) AP-2 complex subunit µ2 + α4
integrin: PDB 5FPI (141).
Figure 5 Structural features of integrin ligand binding – extracellular ligands.
Integrin-ligand interactions are shown on the left for α-I domain containing integrins with the
indicated ligands and on the right for integrins without the α-I domain. Please note that in the
first case only the α-I domain (purple) makes contact to the ligand (green), while in the latter
the heads of both the α- and the β-subunit (red and blue, respectively) contact the ligands
(green). The overview of different RGD ligands with relevant integrins (right hand side)
highlights the structural diversity within this group for both integrins as well as RGD ligands.
It is noteworthy that in α-I domain integrins only one metal ion site is present (MIDAS),
potentially favoring a stricter on-off binding regime due to the missing fine tuning by the
ADMIDAS site. The binding pocket for ligands is also more accessible compared to integrins
without α-I domain (compare e.g. the orientation and peptide presentation of ICAM3 to
fibrinogen binding to aIIbb3). The accessibility might also have an impact on fibronectin
binding, requiring the presentation of the RGD peptide in a short loop to integrins. High-affinity
binding to a5b1 is facilitated by auxiliary binding of fibronectin to the synergy binding site on
a5 (302). Lack of this auxiliary binding might contribute to conformation-specific binding of
aVb3 integrin to fibronectin. The accessibility is also expected to influence TGFb binding; the
RGD peptide in LAP/TGFb is surrounded by a bulky a-helix. Steric hindrance with Tyr122
prevents binding to b3 integrins, in contrast to b6 and b8 (Ala) and b5 (Leu) (see also Fig. 2).
Structures shown: a2b1 + collagen: PDB 1DZI (124); aLb2 + ICAM3: PDB 1T0P (408);
aMb2 + C3d: PDB 4M76 (33); a5b1 + RGD: PDB 3VI4 (302); aIIbb3 + fibrinogen: PDB
2VDO (409); aVb3 + fibronectin: PDB 4MMX (5); aIIbb3 + RGD: PDB 3ZE2 (501); aVb6
+ LAP/TGFb: PDB 5FFO (113).
Figure 6 Protein interplay within integrin-mediated adhesion. This schematic figure
highlights how protein interactions in cell-matrix adhesions are controlled by conformational
regulation of the adhesion proteins. The integrin cytoplasmic domain acts as a binding
platform for several proteins. Talin (yellow) binds with its head domain to the cytoplasmic
domain of the b-subunit and with its tail connects it to the actomyosin machinery. The talin
tail with its rod domains contains actin binding sites (ABS) for initial integrin-actin linkage
(ABS3). Under mechanical load cryptic binding sites of talin open for one or more vinculins
(light pink), as well as F-actin (ABS2) reinforcing the mechanical connection between
integrin and actin (24). Vinculin (the head domain binds talin, the tail domain binds actin) can
also recruit additional adapters and thereby contribute to adhesion signaling (71). Kindlin
(green) co-operates with talin in integrin activation and adapter recruitment as for example
paxillin (335). Paxillin (purple) is an important scaffolding protein, recruited to focal
adhesions via its LIM domains and organizing Rho-GTPase signaling via Paxillin LD
domains. This signaling (indicated by a yellow lightning symbol) is modulated by FAK-Src
(orange, light blue)-mediated phosphorylation. FAK consists of a focal adhesion targeting
domain binding to paxillin, a kinase domain and a FERM domain binding to the lipid
membrane. Interactions in this web are very dynamic, with binding and unbinding events in
quick succession. Accordingly, a one-to-one pairing is not to be expected. Instead, a mutual
connectivity between the tension-defined ECM-integrin-talin-actin axis and perpendicular
interactions based on the paxillin/FAK/talin signaling axis will reinforce and stabilize the
adhesion-structure (slanted fence model; see Chapter 4).
Figure 7 Interplay between focal adhesion and microtubules. Ligand-bound integrins
are in closer proximity to the substrate compared to the surrounding membrane. The core of
integrin-mediated adhesions is densely populated and might differ from the ‘outer shell’.
Microtubules and focal adhesions are linked via Kank proteins at this outer shell, which
directly interacts with the talin rod domain (52). While kank can destabilize the talin
association with F-actin (420), it also links talin to CLASP proteins and the liprin scaffold.
CLASP is important for recruitment of microtubules to adhesion sites, which in turn controls
the localized release of proteases (410). The link of kank-proteins to the liprin scaffold directs
vesicular trafficking to the cell periphery, involved in directed fibronectin release at sites of
adhesion to mediate fibrillogenesis (278), as well as to induce cell spreading during cancer
cell migration (86).
Figure 8 Integrin activation cycle. Integrins show the inactive, bent conformation in
absence of intra- or extracellular adapters. The transmembrane domains are closely associated
to support this bent structure (BC = Bent-Closed conformation). The activation process may
involve both extracellular (ligand) and intracellular (talin, kindlin) triggers, leading to
extension (EC = Extended-Closed) and priming (EP = Extended-Primed) of the integrin,
which facilitates early adhesion events (see also Figure 3). For full activation, integrin legs are
separated and arranged in the direction of the actomyosin force-vector (EO = Extended-Open
conformation). The activation of integrins is accompanied by the recruitment of signaling
(paxillin, FAK) and structural (talin, vinculin) adapters. Recycling of integrin-mediated
adhesions can occur via integrin inactivation (as shown in Figure 4), with integrin
phosphorylation being an important step. The release of talin allows binding to endocytosis
adapters like Dab2, and subsequent recycling via the sorting nexin 17 (SNX-17) (35, 265).
Integrins can also be internalized together with their ligands (397, 398) potentially influencing
their capacity to signal from the endocytotic pathway (11) .
Figure 9 Mechanoregulation of cell adhesion. Many of the proteins participating in cell
adhesion have an autoinhibited state. Shown here is fibronectin, which has a globular
conformation when the protein is in the soluble state. Inactive integrin shows a closed, bent
conformation. Also the intracellular protein talin exists in an autoinhibited state, where the rod
domain is in contact with the head domain (163). The first step in the activation process is called
“chemical activation”, where conformational changes take place, leading to insoluble fiber
formation and collagen binding in the case of fibronectin. Integrin activation can be triggered
both by extracellular and intracellular signals, such as metal ions (289), RGD-ligand proteins
(427) and talin (484). Talin may become activated by lipid-mediated triggers, such as increased
PIP2 concentration (262, 380). Some of the ligands such as RIAM (170, 244) and DLC1 (491)
bind only to relaxed talin. For full maturation, the adhesion complex requires mechanical
signals. This leads to changes in the properties of ECM, controlling e.g. the binding of growth
factors (317). In the case of integrin, mechanical load is needed for the complete activation,
where leg separation takes place (500). The mechanosensory role of talin is studied widely and
it involves the exposure of binding sites for other adapter proteins, including vinculin (206,
365). Additionally, mechanical tension also leads to dissociation of certain binding partners
such as RIAM and DLC1 (170, 178). Finally, to recycle the adhesion, cells may utilize several
molecular mechanisms. Proteolytical cleavage of ECM and intracellular proteins may be
involved in the adhesion disassembly (4, 144, 221). Phosphorylation of integrin can be used to
tune the binding affinity towards various intracellular partners (14).
